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ANTERIOR PITUITARY G-LAND.
SUMMARY
Forty-one boya and twenty-nine girls were studied and sixty-
seven of these children were investigated because of their small
size. Attention was paid to the following points in the history
and clinical examination! chief complaint, birth weight, birth
order, pregnancy and confinement, maternal age at birth, parental
heights, height and skeletal age, and the age at which "small sire"
was noticed.
Tests of anterior pituitary function were applied and these
were based upon the response of target organs. Eighteen children
were found to have a primary disease process initially unrelated to
the anterior pituitary, and certain of these were discussed, e.g.
chronic regional ileitis, and erythrogenesis imperfecta with
transfusion haemosiderosis. The association of anaemia with
hypopituitarism in two girls was considered, and twelve children
with a history of convulsions were examined in detail.
Thirty-seven children were investigated using all the tests of
endocrine function available in this study. They showed no
clinical evidence of a destructive pituitary lesion and they were
grouped according to their biochemical findings. No conclusive
evidence was obtained on comparison of these groups with certain
physical attributes, e.g. birth wei^it and parental height.
A classification of endocrine disorders of growth in
pre-pubertal children based upon biochemical defects was proposed
for research purposes.
Metabolic studies with Human Growth Hormone were carried out
in four children and they showed variable responses but no evidence
of hypercaleiuria which has been described by others.
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INTRODUCTION
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Those individuals who fall markedly below the average height
of a species may be termed "dwarfs". There are ethnic dwarfs as
well as dwarfed individuals in normal races, and there is frequent
reference to dwarf growth in the legends and literature of most
languages. The early reports have been exhaustively, if
uncritically, reviewed by Rischbieth (1912)•
Most of the causes of dwarfism in children are ?;ell-known and
are listed in the standard texts (e.g. Mlkins, 1957)- They
include primaiy skeletal abnormalities, nutritional disorders and
renal disease. Many of these causes may be excluded on clinical
examination alone, but there is a large group of children which
defies accurate diagnosis and this includes the so-called genetic
and endocrine dwarfs.
Kundrat (1891) was the first to show that many varied
pathological processes could produce shortness of stature.
Previously, investigation was confined to measurement and detailed
clinical description, which caused the literature to be
overburdened with eporyms and which created chaos in classification.
It was Hutchison (1900) and Benda (1900) who first suggested the
possible role of the pituitary gland in dwarfism, and in one of
three cases reported by Levi (1908) there were definite clinical
signs of a pituitary lesion. Since Erdheim's description of a
dwarf with a pituitary tumour (1916), there have been several
recorded instances of dwarfs with proven hypophyseal lesions
9
(e.g. Falta, 1927), but in most cases the aetiologr remains
unknown.
The scientific investigation of pituitary function was not
begun until the late 19th centuxy when attempts were made to study
the effects of ablation in animals. Reports of such experiments
were conflicting until Smith (1916) and Allen (1916), working
independently, showed that hypophysectomy in the early frog embryo
resulted in thyroid atrophy, a failure of metamorphosis, a slow
rats of growth, and a reduction in the number of aelanophores and
pigment granules. The subsequent discovery by Evans and Long (1922)
of the growth-enhancing effect of an anterior pituitary extract in
the rat, along with Smith's description (1926) of the
parapharyngeal approach for hypophysectomy formed the basis for the
future understanding of pituitary physiology.
The early indications that the pituitary was concerned with
somatic growth in mammals (e.g. Crowe, Cushing and Homans, 1910J
Aschner, 1912) were confirmed in 1930 when Smith reported that the
most profound effects of hypophysectomy in the rat were dwarfism,
atrophy of the thyroid, adrenal cortex and gonads, loss of libido,
and the failure of liver, spleen and kidneys to achieve a normal
weight. Smith also noticed the persistence of infantile
characteristics in the young hypopbysectomised animal and he
described how the daily administration of fresh pituitary extracts
caused complete reversal of his findings.
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Such fundamental experiments stimulated research in
biochemistry and in its allied disciplines. During the past
twenty years with new and refined methods of protein fractionation,
there have been many reports on the isolation and characterisation
of the active principles of the anterior pituitary. Thus Li, Evans
and Simpson (1943) and Sayers, White and Long (1943) extracted
adrenooorticotrophic hormone from sheep and ox pituitaries, and
this led to the isolation of a melanocyte-stimulating factor by
Lerner, Shizume and Bunding (1954). Further studies on the
specific growth-promoting hormone resulted in the isolation of
highly purified crystalline preparations by Li, Evans and Simpson
(1945) and Wilhelmi, Fishman and Russell (1948). At present seven
anterior pituitary hormones are available in pure form or as
compounds with high specific activity; these are
adrenocorticotropic hormone (ACTH), follicle-stimulating hormone
(FSH), growth hormone (GH), luteinizing hormone (LH), melanocyte-
stimulating hormone (MSH), prolactin (P), and thyroid-stimulating
hormone (TSH).
The recognition of these compounds has led to the development
of methods of assay but as yet none of these is applicable to
routine clinical use. Anterior pituitary function must therefore
be assessed by the measurement of the responses of the target
organs. It is not uncommon to find instances of dwarfism which
have been ascribed to endocrine causes on the most equivocal
IX.
observation. Rational therapy cannot be based upon assumption,
therefore the work of this thesis was undertaken to investigate
disorders of growth in children with particular reference to the
anterior pituitary gland.
The studies to be described form three sections. The first
is concerned with the evaluation of the endocrine status of
dwarfed children using tests of end-organ function, the second
comprises metabolic studies with human growth hormone, and the
third deals with methods of assay of human growth hormone in serum
or plasma.
SECTION 1
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Twenty-nine girls and forty-one boys were studied during the
author's tenure of the post of Registrar to the Department of
Chemical Pathology, The Hospital for Sick Children, Great Ormond
Street» Sixty-seven of these children were investigated on
account of their small sise even where the initial complaint was
apparently unrelated. Two boys, in whom a diagnosis of suprasellar
neoplasm had been made, were included in this series, despite the
fact that one was about the 45th percentile for height (against
chronological age). A third boy, who was not dwarfed, was also
considered. It was suspected that he had a pituitary lesion.
The approach to the study of disorders of growth in this
instance was essentially biochemical, but particular attention was






Maternal age at birth.
Parental heights.
Height and weight of patient.
Age at which disturbance of growth was noted.
It was not possible to obtain adequate data in all of the
13.
children because three were adopted, two were private patients,
and in others there was no opportunity to take or to confirm a
history.
The tests of anterior pituitary function were based upon
measurements of the response of the target organs. These
investigations were considered the best at our disposal:-
The insulin tolerance test.
The response of the adrenal gland to exogenous
and endogenous ACTH.





Thyroid uptake of I.
Urinary gonadotrophins •
Again, it was not possible to apply all of these tests in
each child.
The values obtained from the history on maternal admission are
approximatej for example, it was not possible to verify details of
each pregnancy and confinement from medical records and the
results must serve only as a guide for further enquiry. It was not
possible, again, to make accurate measurements of parental heights.
14.
The age at which "small size" was noted is also open to subjeotive
variation and the results must be considered with reservations.
The heights and weights of the children studied were
measured in the Growth Clinic (Dr, J,M.Tanner), or on the ward in
the case of those children who were not referred to that clinic*
Data on the history and physical examination are given in




Chief complaint Number of
patients
Small size. 19
Small size and convulsions. 3
Small size and obesity. 1
Small size and mentally handicapped. 1
Convulsions. 2
Headaches. 3
Headaches and fits. 1
Failure to thrive and recurrent cough. 1
Persistent cough, obesity and constipation. 1
Failure to thrive and offensive stools. l
Anorexia, sickness and diarrhoea. l
Vomiting and failure to thrive. 1
Undescended testes and small penis. 1
Undescended testes. 1





Chief complaint Number of
patients
Small size. 15
Poor appetite and failure to gain weight. 5
Failure to thrive and convulsions. 4
Physical and mental retardation. 3
Eczema. 1











3 Normal, full-term, spontaneous vertex
delivery.












4 Normal, full-term, spontaneous vertex
delivery.
7 4 lb 1 Abdomen small during pregnancy. Normal,
full-term, spontaneous vertex delivery.
8 6 lb
4 oz
















2 Normal, full-term, spontaneous vertex
delivery.








2 Normal, full-term, spontaneous vertex
delivery.













1 Mild toxaemia, full-term, spontaneous
vertex delivery. Rapid 2nd stage.
"Asphyxia livida" twitchings after birth.
18 5 lb
14 oz







2 Normal, full-term, spontaneous vertex
delivery.
21 7 lb 1 Small haemorrhage for 5 days during 1st
month. Spontaneous vertex delivery.




1 Normal, full-term, spontaneous vertex
delivery. Abdomen "small during pregnancy".
24 7 lb
14 oz




2 Toxaemia, Caesarean section at 7 months.
26 3 lb
6 oz
1 ? full-term. Abdomen small during
pregnancy. Doctor uncertain at 4 months.
Very poor intra-uterine movements. First
stage - 3 days, second stage - 2 hours.
Very small placenta. Cyanosis at birth.
27 3 lb
10 oz
3 Premature birth at 30-31 weeks gestation.
Normal delivery.



































9 2 months premature, spontaneous delivery.
Smallest and sole survivor of triplets.
36 5 lb
13 02
1 Pull-term, 36 hour labour, forceps
delivery for foetal distress.
37 Not
stated
3 Normal, full-term, spontaneous delivery.
38 7 lb
4 oz




1 43 weeks duration, 3 day labour,
forceps delivery.
40 4 lb 4 Toxaemia. ? occipito-posterior position.
2 weeks premature by dates.
41 7 lb 2 Hyperemesis gravidarum. 8 months
gestation. Breech presentation.
Forceps delivery. General anaesthesia.
Shock and cyanosis at birth.
fable 3
BIRTH IEIGHT












2 Not premature by dates. Caesarean section
for uterine inertia first pregnancy.
4 5 lb 2 Normal, full-term, spontaneous vertex
delivery. Poor condition at birth.
5 7 lb
4 oz




5 Normal, full-term, spontaneous vertex
delivery.
7 6 lb 5 Normal, full-term, breech delivery.




2 Normal, full-term, spontaneous vertex
delivery.






1 Normal, full-term, spontaneous vertex
delivery.




3 Salmonella infection at 3 months.
43 weeks duration. Face presentation.
16 4 lb Not
stated
Severe ante-partum haemorrhage at 2 months.



















Normal, full-term, spontaneous vertex
delivery.
19 3 lb 1 Normal, full-term, breech presentation,
forceps delivery.




2 8 month pregnancy, spontaneous vertex




2 Normal, full-term, twin pregnancy.
Spontaneous delivery. Twin still-bora,












2 External cephalic version, breech
presentation. Ante-partum haemorrhage
followed by surgical induction.
28 4 lb
2 oz








MATERNAL AGE AT PATIENT'S BIRTH
BOYS




























MATERNAL AGE AT PATIENT'S BIRTH
GIRLS




















Skeletal age is a radiological measure of the developmental
status of the bones and it has been the most commonly used
indicator of physiological maturity (Tanner, 1962). Although the
assessment is approximate, it is of particular value in clinical
paediatrics and its diagnostic use in relation to endocrinology
has been described (Mellman, Bongiovanni and Hope, 1959)*
The method used in the present study was that described by
Greulich and Pyle (1959)» in which a given X-ray was compared with
standards derived from a vezy large series of children. Briefly,
a film of the left wrist was compared with the standard for the
same sex and nearest chronological age in the Atlas. The film was
then matched with adjacent standards which appeared to resemble it
most closely on superficial examination. A more detailed study
was next made of each individual bone, and lastly, a mean value
was assigned to the entire wrist and hand.
All assessments were made on the left hand in accordance with
established custom. According to Greulich and iyLe (1959)» except
in grossly pathological states the difference between the right
and left side is negligible when one compares the entire wrist and
hand.
It has already been stated that assessments of skeletal age
are approximate. The application of more rigorous standards in
24
this country must await publication of those values for skeletal
maturity which are based upon a study of three thousand British
children (Tanner, Hfhitehouse and Healy, 1961). Ellis (1962), has
written that Greulich and fyie standards, which were founded upon
North American data, are not strictly applicable to other
populations and he stated that allowance must also be made for
secular change.
The precision of the Greulich-fyie standards demands exact
positioning of the hand for X-ray and the assessment of each film
is open to subjective error. Thus, Mainland (1953,1954), has
shown that the consistency of performance of a single observer is
such that only two-thirds of duplicate assessments fall within
six months. Yet another source of error is found in the rating
of different bones in the wrist which show different skeletal ages
in relation to the standards. There is no agreement as to how
















3 10.53 7y 2m 67 66
4 3.74 ly 4o 63 58
6 8.52 5y 0m 67.5 64
7 4.48 3y 3® 71.5 66.5
9 2.15 Qy 10m 64.75 61.5
10 2.49 ly 10m 66 64
11 5.92 2y 6m 66.5 62
12 10.32 8y Om 68.5 64
16 1.17 Qy 6m 75 64
18 8.08 4y 2m 69 62
19 11.94 7y 6m* - 60
21 2.42 Qy 7go 69 67
22 14.07 Sty Om 72 65
23 7.6 4y Om 69 62
24 11.06 7y 6m 61.5 61.5
25 14.02 lQy 9® 72 68.5
28 14.5 8y 3m 63.75 61
29 13.43 8y Om 60 64.5
31 8.1 4y 6m - 64
32 3.65 2y 7m 68 61
33 4.98 ly 9m 68 60
35 10.0 6y 3m 62 62
36 7.38 5y lm 71.5 61
38 7.59 4y 5m 71 67
39 9.56 4y 9a 70 61
41 13.25 8y 9m 68 68















2 1.31 lOgm 70 61
3 2.75 ly 11m 67 58
6 4.92 2y 9m 63 63
8 6.66 4y 9m 63 62
9 2.0 ly 4m 70 64
10 4.99 3y 9m 65 59.5
12 6.75 3y 6m 68 61
16 9.92 6y 4m 63 61
17 6.67 5y 64 61.5
19 3.58 2y 5m 71 59
20 9.52 4y 64.5 62.8
22 11.98 6y 8m 72 64
23 3.91 2y 4m 66 64
25 1.5 ly 5m 62 62
26 9.25 - 68.5 65.5
27 16.55 Hjr 72 60
28 8.63 7y 6m 67 62
29 2.33 2y 2m 67 61.5
Table 8, 27.
HEIGHT AND WEIGHT
PERCENTILE RATINGS FOR SKELETAL AGE
BOYS







2 14.45 lly Om 149.1 90 40.9 95
3 10.53 7y 2m 124.0 70 24.8 80
4 3.74 ly 4a 77.6 30 7.0 <3
5 2.08 ly 3® 80.0 70 8.75 <3




7 4.48 3y 3® 91.9 17 11.18 <3
8 13.92 14y Om 133.75 <3 31.16 <3
9 2.15 Qy 10m 79.3 >97 9.1 25
10 2.49 ly 10m 82.2 Just
below 25
9.9 4
11 5.92 2y 6m 85.3 7 11.1 5
12 10.32 8y Om 108.8 <3 19.7 5
13 14.6 14y Om 150.8 Just
below 25
43.21 45
14 2.25 9-12m 81.2 <97 7.8 >3
16 1.17 Oy 6m® 65.9 40 6.65 12
18 8.08 4y 2m 108.75 Just
1 above 90
17.3 80
19 11.94 7y 6m® 128.75 85 42.56 >97
20 8.25 5y Om* 105.9 35 18.29 45
21 2.42 7.5® 68.3 40 7.7 20
22 14.07 5y Om 120.5 6 24.5 20
23 7.6 4y Om 105.2 80 17.1 60
24 11.06 77 6m 111.2 <3 22.7 37
* Estimated by Dr. M.E.Sidaway.




PERCENTILE RATINGS FOR SKELETAL AGE
BOYS
(Continued)










25 14.02 lQy 9» 136.5 35 43.9 >97
28 14.5 8y 3® 130.6 75 25.6 60
29 13.43 8y Om 128.1 70 42.7 >97
30 7.76 9y 3m 123.6 7 25.8 Just
below 25
31 8.1 4y 6m 99.8 Just
above 10
14.4 7
32 3.65 2y 7m 83.4 < 3 9.2 <3
33 4.98 ly 9m 78.8 7 8.7 <3
34 7.75 2y 6m* 91.25 45 17.27 >97
35 10.0 6y 3m 115.5 50 16.7 4
36 7.38 5y lm 103.1 10 18.86 50
37 2.79 Qy 9m 81.8 >97 11.2 94
38 7.59 4y 5m** 113.1 97 18.86 75
39 9.56 4y 9m 110.7 82 22.5 >97
40 15.28 lOy Om 131.3 Just
below 25
39.8 >97
41 13.25 8y 133.4 Just
above 75
33.2 96
♦ Estimated by Dr. J.S.Sutcliffe at chronologioal
age 7,33 years.
*.* Estimated two weeks after height and weight.
< = less than, > = more than.
Table 9.
HEIGHT AND WEIGHT
PERCENTILE RATINGS FOR SKELETAL AGE
GIRLS










1 7.08 3y 3m 87.5 Just
below 3
10.76 <3
2 1.31 lOgm 70.0 25 7.6 7
3 2.75 ly 11B 78.1 Just
below 3
8.5 <3
4 5.5 3y 3m - - 17.2 93
5 13.11 10y 125.4 7 23.3 4
6 4.92 2y 9m 96.3 94 14.7 77
8 6.66 4y 9m 102.5 23 16.1 24
9 2.0 ly 4a 76.25 25 10.0 37
10 4.99 3y % 97.3 37 12.1 <3
11 13.17 8y 3m 125.8 50 25.9 67
14 1.66 11m 74.0 75 8.21 16
16 9.92 6y 4a 115.9 Just
above 50
21.08 65
17 6.67 5y 100.5 7 13.6 <3
18 8.79 2y 4m 109.4 >97 28.1 >97
19 3.58 3y 5m 87.0 30 9.5 < 3
20 9.52 4y 93.0 3 14.2 11
21 12.22 lQy 6m 127.5 7 22.9 <3
22 11.98 6y 8m 111.3 22 19.1 17
23 3.91 2y 4m 80.6 < 3 10.68 8
25 1.5 ly 5® 83.1 95 10.9 55
27 16.55 lly 128.6 4 29.8 23
28 8.63 7y 6m 115.4 12 18.6 Just
above 3
29 2.33 2y 2m 76.6 <3 8.7 <3
= less than. = more than.
Table 10.
HEIGHT AND 1EIGHT
PERCENTILE RATINGS FOR CHRONOLOGICAL AGE
BOYS










2 14.45 lly Om 149.1 Just
below 10
40.9 17
3 10.53 7y 2m 124.0 <3 24.8 4
4 3.74 ly 4m 77.6 <3 7.0 <3
5 2.08 ly 3m 80.0 <3 8.75 <3
6 8.52 5¥ Om 114.4 <3 19.72 <3
7 4.48 3y 3m 91.9 <3 11.18 <3
8 13.92 14y Dm* 133.7f <3 31.16 <3
9 2.15 Qy 10#* 79.3 <3 9.1 <3
10 2.49 ly 10m 82.2 <3 9.9 <3
11 5.92 2y 6m 85.3 <3 11.1 <3
12 10.32 8y Om 108.8 <3 19.7 <3
13 14.6 14y Om 150.8 Just
below 10
43.21 <3
14 2.25 9-12m 81.2 <3 7.8 <3
15 9.91 - 108.4 <3 27.95 30
16 1.17 QyG&** 65.9 <3 6.65 <3
17 6.16 - 112.8 30 20.31 48
18 8.08 4y 2m 108.75 <3
|
17.3 3
19 11.94 7y 128.75 <3 42.56 91
20 8.25 5y Om*** 105.9 <3 18.29 <3
21 2.42 7.5m 68.3 <3 7.7 <3
22 14.07 9y Om 120.5 <3 24.5 <3
23 7.6 4y Om 105.2 <3 17.1 <3
24 11.06 7y 6m 111.2 <3 22.7 <3
* Estimated by Dr. J.S.Sutcliffe 20 weeks after
height and weight, and after steroid therapy.
** Estimated one week before hei^it and weight.
*** Estimated by Dr. M.E.Sidaway.
(Continued)
< = less than. > = more than.
HEIGHT AND WEIGHT



















27 5.66 - 98.75 <3 14.68 <3
28 14.5 8y 3m 130.6 <3 25.6 <3
29 13.43 8y Om 128.1 <3 42.7 70
30 7.76 97 3m 123.6 45 25.8 Just
above 75
31 8.1 4y 6m 99.8 <3 14.4 <3
32 3.65 2y 7m 83.4 <3 9.2 <3
33 4.98 3y 9m 78.8 <3 8.7 <3
34 7.75 2y 6m* 91.25 <3 17.27 <3
35 10.0 6y 3m 115.5 <3 16.7 <3
36 7.38 5y lm 103.1 <3 18.86 6
37 2.79 0y 9m 81.8 <3 11.2 <3
38 7.59 4y 5m** 113.1 3 18.86 4
39 9.56 4y 9m 110.7 <3 22.5 4
40 15.28 lQy Om 131.3 <3 39.8 4
41 13.25 8y 9m 133.4 <3 33.2 7
* Estimated by Dr. J.S.Sutcliffe at
chronological age 7.33 years.
** Estimated two weeks after height and weight.
= less than. > = more than.
Table II.
HEIGHT AND WEIGHT
PERCENTILE RATINGS FOR CHRONOLOGICAL AGE
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GIRLS










1 7.08 3y 3m 87.5 <3 10.76 <3
2 1.31 10|m 70.0 <3 7.6 <3
3 2.75 ly 11m 78.1 <3 8.5 <3
4 5.5 3y 3m - - 17.2 17
5 13.11 lQy 125.4 <3 23.3 <3
6 4.92 2y 9m 96.3 <3 14.7 5
7 2.33 - 80.5 <3 9.9 <3
8 6.66 4y 9m 102.5 <3 16.1 <3
9 2.0 ly 4m 76.25 <3 10.0 6
10 4.99 3y 9m 97.3 <3 12.1 <3
11 13.17 8y 3m 125.8 <3 25.9 <3
12 6.75 - 95.6 <3 16.7 <3
13 13.5 4Mb 116.7 <3 26.56 <3
14 1.66 11m 74.0 <3 8.21 <3
16 9.92 6y 4m 115.9 <3 21.08 <3
17 6.67 5y 100.5 <3 13.6 <3
18 8.79 2y Am 109.4 <3 28.1 75
19 3.58 2y 5m 87.0 <3 9.5 <3
20 9.52 4y 93.0 <3 14.2 <3
21 12.22 lQy 6m 127.5 <3 22.9 <3
22 11.98 6y 8m 111.3 <3 19.1 <3
23 3.91 2y Am 80.6 <3 10.68 <3
25 1.5 ly 5m 75.3 <3 8.47 <3
26 9.25 - 106.9 <3 18.57 <3
27 16.55 ny 128.6 <3 29.8 <3
28 8.63 77 6m 115.4 <3 18.6 < 3
29 2.33 2y 2m 76.6 <3 8.7 <3
^ » less than. = more than
Table 12.
"""" JJ*
AGE AT WHICH SMALL SIZE WAS FIRST OBSERVED
BOYS
Age Patient
0-1 year 3, 4, 5. 7, 9, 10, 11, 12, 14, 15, 16,
18, 21, 26, 29, 32, 33, 35, 36, 39.
1-2 years 37, 40.
2-3 years 24, 25, 34, 41,
3-4 years 6, 22, 31.
4-5 years 23.
5-6 years «oCM
Normal at 5 years,







2, 8, 13, 17, 27, 30, 38.
Total number of patients = 40
GIRLS
Age Patient
0-1 year 2, 4, 10, 11, 13, 14, 16, 17, 19, 20,
21, 22, 25, 26, 27, 29.
1-2 years 6, 9, 28.
2-3 years •<30
3-4 years 12, 18.
7-8 years 5.
Total number of patients = 24
34*
THE INSULIN TOLERANCE TEST
Eraser, Albright and Smith (1941) discussed the value of the
intravenous insulin tolerance test in the diagnosis of endocrine
disorders of carbohydrate metabolism and they stated that the test
had two purposes:-
a. to measure the sensitivity of the blood glucose level to
insulin,
b. to measure the "responsiveness" of the blood glucose level to
an insulin-induced hypoglycaemia.
It was concluded that the test was of value in differentiating
pan-hypopituitarism from some cases of anorexia nervosa and from
primary hypothyroidism.
McQuarrie (1954) upheld the value of the investigation
particularly in the study of hypoglycaemia in children, but
Martin and V/ilkins (1958) wrote that they had not employed the
insulin tolerance test for some years because of the danger
inherent in the intravenous use of insulin and because of the
difficulty in the interpretation of the results. The hazards of
intravenous insulin are not denied but children respond to the test
in the same manner as adults even when the insulin is given
subcutaneously. Clayton (1962), with experience of some
two hundred investigations, has found the subcutaneous insulin
tolerance test to be a valuable screening procedure in suspected
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hypofunction of the anterior pituitary or adrenal cortex, provided
the child is under constant nursing surveillance.
Procedure: - The method is that of Daniel (1941), which as he
claimed is relatively simple to perform and which obviates the
need for expensive apparatus. The child is tested in the fasting
state preferably in the morning. The diet prior to the test
should be the normal one for the age in so far as the clinical
condition will permit (Himsworth, 1959) • After the collection of
a fasting blood sample by heel or finger-prick, a standard dose of
0.25 units of soluble insulin per kilogram of body-weight is
injected subcutaneously. Further blood samples are taken at
20, 40, 60 and 120 minutes after the administration of the hormone
and total blood reducing substances are estimated by micro-method
(Wilkinson, i960)• In children of short stature or in suspected
cases of hypopituitarism or hypoglycaemia, 0.125 units of soluble
insulin are given per kilogram of body-weight and this is called
an "half-strength" tolerance. The child is under constant
nursing supervision throughout the test, and if the clinical
condition demands the investigation is stopped by the
administration of oral glucose after the collection of a blood
sample. In this series only one child required the administration
of intravenous glucose.
Interpretation:- The interpretation of the test lies in the
form of the curve. Following the administration of insulin, in
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THE INSULIN TOLERANCE TEST
TYPICAL RESPONSES
THE INSULIN TOLERANCE TEST. TYPICAL RESPONSES





Fasting 20 40 60
Minutes after Insulin
Ms. '
the healthy child the blood sugar level falls during the first
thirty minutes, and reaches the lowest value by the end of the
first hour, returning to fasting level by the 120 minute sample.
The difference between the fasting blood sugar and its lowest
level ranges from 15 - 25 mg./iOO ml. (see Pig. l).
Fraser and Smith (1941) expressed "hypoglycaemia
unresponsiveness" quantitatively, by measuring the slope of the
curve after the maximal fall had been reached; this is
unnecessary. These authors also found that to a limited extent,
the degree of failure to respond to hypoglycaemia corresponded to
the degree of pituitary failure on clinical assessment.
An excessively steep fall in blood sugar with a slow return
or a failure to achieve fasting values is seen in adrenal or
pituitary insufficiency, starvation, glycogen storage disease,
galactosaemia and gastro-intestinal disturbance with poor
absorption of glucose (Hartmann and Jaudon, 1937)*
Excepting the newborn, the average normal response is almost
the same in infants and older children. Healthy newborn infants
with physiological hypoglycaemia have a low tolerance (Hartmann
and Jaudon, 1937)*













20 40 60 120
1 7.0 • 122 79 74 68 68
2 14.45 lly Om 137 79 50 58 47
4 3.74 ly 4m 87 83 63 84 64
5 2.08 ly 3m 95 59 50 59 55
6 8.52 5y Om 73 85 80 70 75
7 4.48 3y 4m 81 81 66 69 75
8 13.92 14y Om* 100 91 69 65 50
9 2.15 Oy 30m-* 90 63 50 38 54
10 2.49 ly 10m 81 81 76 81 71
11 5.92 2y 6m 81 75 56 69 69
12 10.32 8y Ora 100 113 62 62 69
13 14.6 14y Om 89 87 87 89 89
14 1.75 Oy 6m 78 78 70 85 75
15 13.75 - 88 76 58 58 61
16 1.17 Qy 6m*®* 63 42 45 45 32
17 6.16 *0 95 84 71 50 50
18 8.08 4y 2m 112 82 76 89 106
19 11.94 7y 6m*** 67 62 62 60 55
20 8.25 92 100 82 66 74
21 2.42 Oy Tgffl 48 26 24 21
22 13.08 8y Om 95 83 68 66 72
23 7.6 4y Om 92 83 72 67 56
• Estimated by Dr. J.S.Sutcliffe 20 weeks after
height and weight, and after steroid therapy.
Estimated one week before height and weight.
*** Estimated by Dr. M.E.Sidaway.











(m = mths) Fasting
Minutes after insulin:
20 40 60 120
25 14.02 lQy 9m 70 65 60 65 65
27 5.58 - 78 75 66 53 30
28 14.5 8y 3m 84 84 69 71 106
29 13.43 8y Om 78 78 72 69 69
30 6.83 "far Om 90 87 76 76 76
31 8.1 4y 6m 83 66 48 57* 48
32 3.65 2y 7m 90 74 53 50 47
33 4.98 ly 56 38 44 38 25
34 7.75 2y 6m** 75 48 35 33 33
35 10.0 6y 3® 100 85 75 72 69
36 7.38 5y lm 118 82 67 67 63
37 2.79 Qy 9® 95 105 81 58 63
38 7.59 4y 5m 89 79 81 73 68
39 9.56 4y 9m 87 86 84 77 75
40 15.28 IQy Om 83 71 79 71 69
41 13.82 StY 6m 100 76 28 39* -
* Oral glucose given after 60 minute sample.
** Estimated by Dr. J.S.Sutcliffe at













Fasting 15 30 45 60 120
3* 9.3 5y 6m 96 87 87 84 84 89
24 11.1 7y 6m 108 80 63 - 29* 50
* Full-strength insulin tolerance.
"HALF-STRENGTH* INSULIN TOLERANCE
BOYS
Patient Chronological Skeletal Blood sugars (mg./lOO ml.)
age
(years)
£££ Minutes after insulin:




110** 52 36 42 40
Oral glucose given after 60 minute sample.











(m = nths) Fasting
Minutes after insulin:
20 40 60 120
4 3.74 ly 4m 86 63 56 52 54
6 8.52 5y Om 116 95 50 85 50
7 4.43 3y 3m 81 81 69 69 60
13 14.6 14y Om 88 86 64 59 46
14 1.75 Oy 6m 81 58 69 69 66
15 13.75 - 89 89 68 63 63
18 8.08 4y 2m 89 74 58 58 56
25 14.02 10y 9® 83 86 77 80 74
28 14.5 8y 3® 88 68 60 60 58
29 13.43 8y Om 80 80 75 68 68
37 2.79 Qy 9m 90 42 50 50 65
38 7.59 4y 5m 89 78 53 60 53










(m = mite) Fasting
Minutes after insulin:
20 40 60 120
1 7.08 3y 3m 69 56 hi
•
38 44
3 3.81 ly 11m 95 77 74 72 82
4 5.54 3y 3m 66 55 55 52 47
5 13.11 lQy Om 95 95 69 69 62
6 4.92 2y % 78 61 48 45 40
7 2.33 - 100 100 - 76 88
8 6.66 4y 9m 80 60 52 63 57
9 1.96 ly Om 86 76 65 60 57
10 4.99 3y 9m 95 90 80 85 85
11 13.17 8y 3m 81 81 65 65 70
12 6.75 3y 6m19 97 84 79 81 66
13 13.5 lOy OmP* 83 88 81 86 91
14 1.89 Oy 11m 100 74 58 68 58
15 4.56 "frrossiy
retarded1
45 39 30 28 34
16 9.92 6y 2m 69 81 75 67 58
17 6.66 5y 5m 91 88 82 82 76
18 8.91 3y 8m 89 78 61 61 63
19 3.58 2y 5m 79 79 66 66 65
20 9.52 4y Om 42 35 25 25*** «■»
21 12.22 lQy 6m 105 90 85 80 80
22 11.98 6y 8m 106 100 94 100 75
23 1.5 Oy 10m 95 95 86 86 88
24 11.17 "Retarded' 84 95 63 63 58
25 1.51 ly 4m 60 55 45 50 50
26 8.6 About
5y**
138 126 130 130 132
* Estimated by Dr. R.D.Hoare.
** Estimated by Dr. M.E.Sidaway.











(m = nihsj Fasting
Minutes after insulin:
20 40 60 120
27 16.55 lly Qm 89 86 62 68 65
28 8.63 7y 6m 86 79 76 73 73
29 2.33 2y 2ra 82 57 62 68 55
Table 16 « 44.
"FULL-STRENGTH" INSULIN TOLERANCE
GIRLS
Patient Chronological Skeletal Blood sugars (mg./lOO ml.)
tit
(years)
(a a mfts) Fasting
Minutes after insulin:
20 40 60 120
3 2.75 ly 11a 63 74 84* 132 58
7 2.33 - 95 62 60 53 50
10 4.99 3y 9m 91 95 91 63 63
12 6.75 3y 6m 91 86 52 58 55
21 12.22 lOy 6m 82 83 «m» 67 61
23 3.91 2y 4a 100 62 54 50 62
26 8.5 5y On 152 120 116 128 116
28 8.63 7y 6m 90 80 75 70 83
"FULL-STRENGTH" INSULIN TOLERANCE
GIRLS














100 97 75 72 69 65
93 93 80 80 84 80
* Drank glucose before 40 minute sample.
•* Estimated by Dr. R.D.Hoare.
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TESTS OF ADRENAL CORTICAL FUNCTION AHD INTEGRITY
OF THE PITUITARY ADRENAL AXIS
The clinical diagnosis of adrenal cortical hypofunction may
be difficult to establish because features such as anorexia,
recurrent dehydration and general debility are not specific for
this condition (Talbot, Sobel, McArthur and Crawford, 1952). Often
the diagnosis is made in retrospect or after the child has been
under clinical observation for several years (Greenberg, 1958).
Among the laboratory investigations which are used as tests
of adrenal cortical function, several are indirect and they
include the measurement ofj-
1. Plasma and urinary electrolytes and blood urea.
2. Absolute eosinophil counts.
3. Ability to excrete a water-load.
4. Insulin tolerance•
In mild degrees of hypofunetion,1 and 2 may be normal. A
water-load test in a patient with suspected adrenal deficiency is
potentially dangerous since water intoxication may result. Also,
such a test may be invalid in the young child who cannot empty his
bladder to order. Insulin tolerance, although useful and safe in
children if performed by the subcutaneous route (Daniel, 1941;
Clayton, 1962) is not specific for adrenal cortical deficiency.
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Chemical methods for assessing adrenal cortical function have
been applied frequently in adults (Nelson, Samuels, V/illardson and
Tyler, 1951; Cordon, Horwitt and Segaloff, 1954), and patterns of
steroid response to adrenocorticotrophic hormone (ACTIl)
stimulation have been clearly defined in various pathological
states (Prunty, 1956)#
In children, as in adults (Prunty, 1956), there is
considerable day to day variation in the excretion of steroids.
Since the urinary excretion of 17-ketosteroids and
17-hydroxycorticolds is so low in children (Noryraberski, Stubbs
and West, 1953; Prout and Snaith, 1958), it is unwise to diagnose
defective adrenal cortical, function by the measurements of resting
steroid excretions. It has been observed in adults that zero
levels of urinary steroids and blood cortiooids are frequently not
encountered in Addison's Disease (Laidlaw, Redely, Jenkins, Haydar,
Renold and Thorn, 1955; Bayliss, 1955). It is, therefore,
necessary to measure the response of the adrenal gland to injected
ACTH in an attempt to demonstrate degrees of adrenal failure.
The test has been employed in several ways in children.
Gottfried, Bogin and Levycky (1957) gave one injection of ACTH in
gelatin solution at 10 p.m. and determined the urinary excretion
of 17-hydroxycorticoids during the following eight hours. Although
a definite rise in steroid excretion was obtained in normal
children, the response was, in fact, so small that it would be
difficult to detect anything other than complete adrenal failure.
4-7
Ely, Raile, Bray and Kelley (1954) measured the
17-hydroxycorticoids in the plasma before and after ACTH. The
values obtained showed a wide variation between individuals, and
the authors considered that rigid interpretation of the results
was unwise as some normal children gave a poor response. The
results obtained by Steiker, Bongiovanni, Eberlein and Leboeuf
(1961), employing a similar type of test, were more regular and
impaired adrenal responses could be diagnosed.
Clayton, Edwards and Renwiek (1962) employed three days*
stimulation with ACTH, since it may take several days to elicit a
near maximal response (Prunty, 1956). The urinary excretion of
corticosteroids was studied in preference to blood because blood
may not be collected at the peak of the response, and diurnal
variations in 17-hydroxycorticoid levels may affect the siae of
the response. In addition, no satisfactory micro-method using
finger-prick blood is yet available for the determination of
17-hydroxycorticoids.
Method of Performing the ACTH Test:
The test was begun at 10 a.m. Four consecutive 24-hour
urine specimens were collected using a few drops of chloroform as
preservative• Twenty physiological units of ACTH gel (H.P.
Acthar gel, Armour Laboratories Ltd.) were administered
intramuscularly at 10 a.m. and 6 p.m. on the second, third and
fourth days. In the course of several hundred tests no unpleasant
side-effect was ever observed.
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Two batches of ACTH of porcine origin were employed: -
1, CK 2501 Initial potency 40 I.U./ml.
Limits = 37.1 - 42.9 I.U./ml.
Fiducial limits (P a 0.95) 87 - 115/.
2. EE 1004 Initial potency 38.4 I.U./ml.
Limits = 34.8 - 42.4 I.U./ral.
Fiducial limits (P a 0.95) 87 - 106/.
Hence 20 units were given in 0.5 and 0.52 ml. gel of batches
CK 2501 and EE 1004 respectively; a tuberculin syringe was used
for injection.
Urinary 17-ketosteroids were determined by the second method
of Prout and Snaith (1958) and total 17-hydroxycortic0ids by the
method of Appleby, Gibson, Worymberski and Stubbs (1955).
Interpretation:
In thirty normal children investigated by Clayton, Edwards
and Renwick (1962), no variation in response was seen with age,
and the eight girls in the group did not give responses
signifioantly different from those of the boys; these
observations confirmed the work of Steiker et al. (1961). As
shown by others (e.g. Gottfried et al., 1957)» the total
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17-bydra:xycorticoids mare a more sensitive .index than the
17-ketosteroids and in the routine investigation there would
appear to be no additional benefit from estimating the
17-ketosteroids. The maximal corticoid excretion occurred during
the second or third days of ACTH administration and, with one
exception, always reached at least 20 mg./24 hours on one or other
of those days.
The normal values employed in this laboratory for
17-ketosteroids and total 17-hydroxycorticoids are as follows:-
17-ketosteroids (Prout and Snaith, 1958)
0-1 year: 0.25 +, 0.12 mg./24 hours (+ standard deviation).
1-5 years: 0.78 + 0.46 mg,/24 hours.
6-10 years: 1.38 + 0.74 mg./24 hours.
11-17 years: 4.96 +, 2.06 mg./24 hours.
Total 17-hydroxycorticoids (Appleby. Gibson. Norymberski and
Jtubbs. 1955).
There is a gradual rise during childhood, with a sharp rise at
puberty.
Up to 10 years: 1.0 - 4.5 mg./24 hours.
10 - 20 years: 4.5 - 19 mg./24 hours, depending on age, sex
and body build.
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In this series of investigations, plasma electrolytes and
blood urea were determined on capillary samples before the
administration of ACTH and on the fourth day of the test. Normal






138 - 143 m.Eq./L.
4.1 - 5.6 m.Eq./L. (up to
6.6 m.Eq./L. in the newborn).
98 - 106 m.Eq/L.
20 - 25 m.Mols/L.
Varies with feed: -
1st year human milk: 15 - 30 mg./lOO ml.
1st year cow's milk: 20 - 45 mg./lQO ml.
Over one year: 20-40 mg./lOO ml.
It is the author's impression that the normal range for serum
or plasma sodium in children is too narrow. Maqy sodium values
from 135 - 138 m.Eq./L. are seen in apparently healthy children.
Similarly, values for blood urea show much wider variation with
diet than one would appreciate from the above normal range.
Measurement of the response of the adrenal cortex to
stimulation by exogenous ACTH will not distinguish between primary
adrenal cortical hypofunction and that which results from
hypopituitarism. There is as yet no means of detecting
circulating ACTH in children with normal or hypopituitary function,
therefore one must use an indirect assay measuring end-organ
response.
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Liddle and his colleagues (1959) described alterations of
adrenal steroid patterns in man following the administration of a
chemical inhibitor of 11-^hydroxylation in cortical synthesis.
These workers proposed a new approach to the evaluation of
"pituitary reserve" which may be defined as the capacity of the
anterior pituitary to secrete ACTH in amounts greater than those
required under ordinary circumstances.
An agent which impairs the synthesis of Cortisol (Liddle,
Island, Lance and Harris, 1958? Jenkins, Meakins and Nelson,1959}
G-old et al., i960), is 2-methyl-l, 2-bis (3-pyric|yl)-propanone
(SU 4885 - CIBA, "Metopiron", "Metopirone"). In low concentration
it is a relatively selective inhibitor of 11-J) hydroxylase. In
consequence of this inhibition, the secretion of Cortisol is
replaced by 11-desoxyeortisol (Compound S). Compound S is an
ineffective suppressor of ACTH secretion; thus as the blood level
of Cortisol falls there is a rise in the adrenal Cortisol
secretion of 11-desoaycortisol, provided the pituitaiy-adrenal
axis is intact. Compound S, and its metabolite "tetra hydro S",
are measurable in blood and urine as 17-hydroxycorticoids.
Method of Performing the Metopiron Test:
The test was begun at 10 a.m. Five consecutive 24-hour
urine specimens were collected using a few drops of chloroform as
preservative, "Metopiron" was administered every four hours for
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twenty-four hours on the third day, in a dosage of 11 rag. per
kilogram body weight. The drug may cause gastric irritation and
rapid absorption may lead to vertigo. Each dose was therefore
given in powder form after milk and a biscuit. The unpleasant
taste was most suitably masked by mixing "Metopiron" with a
flavouring agent - strawberry or raspberry jam proved successful.
In view of the theoretical possibility of precipitating adrenal
failure, intravenous hydrocortisone hemisuccinate was on hand at
the cot-side. In more than one-hundred tests, four children
vomited one or two doses which were successfully repeated in three
cases, and girl patient number 18 felt unwell after the first dose
but recovered within two hours. Blood pressure fell from a
base-line value of 98/70 mm. Hg. to 80/60 during the twenty-four
hour period of "Metopiron" administration.
Urinary 17-ketosteroids were again determined by the second
method of Prout and Snaith (1958), and total 17-hydroxycorticoids
by the method of Appleby, Gibson, Norymberski and Stubbs (1955)•
Interpretation;
In normal adults (i.e. in those in whom there was no reason
to suspect adrenal or pituitary dysfunction), there was a two to
fourfold increase in urinary 17-hydroxycorticoids (Liddle, Island,
Lance and Harris, 1958; Liddle, Estep, Kendall, Williams and
Townes, 1959). The increase was noticeable during the period of
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administration of "Metopiron" but was usually greater in the
following twenty-four hours. A normal range for children has not
yet been published but provisional values show a two to threefold
increase in total 17-hydroxycorticoids on the fourth day of the
test in children over seven years of age (Clayton, 1962). There
is little evidence to suggest that there is apy significant
difference in response to "Metopiron" in children below the age of
seven, in view of the uniformity of response to exogenous ACTH in
children from five months to twelve years (Clayton, Edwards and
Renwick, 1962)•
Arguelles, Chekherdemian and Ottone (1962) found that the
level of the total urinary 17-hydroxycorticoids was a more
sensitive index of response to "Metopiron" in adults than the
urinary 17-ketogenie steroids. In children, it is also true that
the total urinary 17-hydroxycorticoids are a more sensitive and
reliable index than the 17-ketosteroids (Clayton, 1962).
In spite of the fact that it has been shown conclusively in
adults that the administration of "Metopiron" results in the
increased urinary excretion of Compound S and Tetra-Hydro S,
Buus, Binden and Petersen (1962) have challenged the validity of
total urinary 17-hydroxycorticoid determinations on the grounds
that hydrocortisone and Compound S are not specifically
determined. This argument is weakj provided there are
sufficient base-line values, the estimation of total urinary
17-hydroxycorticoids is quite legitimate.
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These Danish workers also questioned the effectiveness of
the four-hourly dosage of "Metopiron" as in blocking
11-3hydroxylase they measured plasma levels of hydrocortisone
and Compound S, a method which may be readily criticised because
of the wide variation between individuals, the fact that the
blood sample may not be collected at the peak of the response,
and that the size of the response may be affected by diurnal
variation*
The results for the ACTH tests are given in Tables 19 and







mg./24 hour8 m«./24 hours
Day 1 Day 2 Day 3 Day 4 Day 1 Day 2 Day 3 Day 4
1 2.3 3.4 3.6 4.1 3.1 14.4 17.0 19.2
2 0.7 1.2 3.4 2.4 5.8 25.2 39.8 20.8
3 1.5 1.8 2.7 6.0 1.5 2.9 16.7 32.9
4 0.4 0.7 0.94 2.5 2.2 11.2 11.3 23.2
7 1.4 1.0 1.0 1.0 1.15 10.0 15.8 17.3
8 2.2 3.1 4.3 4.0 2.4 15.6 23.5 18.2
9 0.9 0.47 0.35 0.36 1.0 2.44 2.0 3.0
10 0.4 0.8 0.7 1.0 1.8 10.7 12.9 15.2
11 0.45 0.9 1.2 1.4 1.8 4.8 6.7 10.0
12 2.5 1.2 3.2 3.6 3.7 6.5 19.0 17.5
13 6.7 11.2 4.8 5.6 12.9 18.7 22.0 32.0
14 0.44 1.0* 1.6 3.5 2.6 6.4* 6.8 13.5
15 1.3 4.3 5.6 4.7 4.5 34.7 36.2 30.5
16 0.2 0.2 0.6 1.0 1.0 2.2 9.3 8.8
17 1.0 1.0 1.0 1.7 4.0 8.4 11.0 18.9
18 0.52 1.2 1.3 1.5 2.3 9.0 12.9 16.0
19 2.9 5.7 7.0 3.6 3.4 17.2 37.8 28.7
20 0.8 1.6 1.4 1.9 1.9 5.5 7.6 12.2
21 0.15 0.2 0.8 1.65 1.13 6.64 12.2 18.5







Patient mg./24 hours mg./24 hours
Day 1 Day 2 Day 3 Day 4 Day 1 Day 2 Day 3 Day 4
22 0.62 1.2 3.6 3.4 3.5 7.3 11.5 26.3
23 1.0 0.5 0.45 2.4 4.3 6.3 15.5 24.2
24 0.8 1.3 0.6 1.1 2.6 14.2 14.1 25.5
25 1.0 2.6 6.8 6.0 4.3 19.3 50.9 53.8
26 0.3 0.24 0.32 0.5 0.45 3.6 5.6 10.3
27 0.8 2.7 1.3 2.5 2.2 12.2 10.4 18.9
28 1.2 2.6 5.0 3.8 4.4 13.5 23.2 18.2
29 0.7 2.0 3.4 3.1 7.5 15.4 41.0 54.7
30 3.1 2.6 5.1 9.7 2.6 12.6 20.1 26.3
31 1.1 1.8 3.5 3.8 2.1 16.8 35.9 26.2
32 0.45 1.7 0.9 0.82 3.1 4.7 10.3 18.9
33 0.2 0.4 0.6 0.9 1.4 6.3 10.2 15.3
34 0.41 1.5 3.6 6.3 1.8 16.9 33.5 38.1
35 1.5 2.4 3.5 5.8 8.4 14.6
36 0.9 1.8 2.65 4.08 4.5 3.6 20.0 24.8
37 2.66* 3.88 1.0 1.46 1.44* 1.43 10.6 17.6
38 3.1 3.7 7.0 5.1 5.8 24.6 39.2 25.0
39 1.1 0.97 1.9 2.8 2.2 12.3 14.7 21.2
40 2.0 5.2 6.2 8.6 2.7 19.2 26.4 26.9
41 0.82 1.15 1.0 2.49 10.3 12.3 14.9 23.6




Patient Sodium Potassium Chloride T.C0„ Blood urea
m.Eq./li # mg./lOO mL
Pre Post Pre Post Pre Post Pre Post Pre Post
1 140 137 5.5 3.6 100 101 - mm - mm
2 140 143 4.4 4.6 106 104 - mm 34 28
3 140 137 5.5 3.6 100 101 mm am - mm
7 139 145 4.2 3.6 102 109 20 20 33 21
8 138 142 5.1 4.4 103 100 26 32 28 22
10 137 138 4.8 4.4 103 103 16 19 25 17
11 138 138 4.3 3.4 101 101 21 23 31 24
13 140 139 4.1 3.9 96 102 - 23 30 19
14 132 135 »CO.m 4.8 97 103 17 21 33 32
15 138 140 4.2 4.2 107 105 21 25 44 30
16 132 - 5.6 - 98 - 18 - 44 -
17 138 143 4.7 3.8 99 108 24 21 34 23
18 140 138 4.8* 3.6 105 106 24 22 12 14
19 142 mm 5.4 - 108 - 26 mm 29 -
20 139 138 5.6 4.3 103 103 20 23 24 33
21 140 - 4.8 mm 109 - 18 mm 43 -
22 137 - 3.5 - 101 - 20 am 19 -
23 138 138 3.7 4.4 106 106 21 21 26 25
24 141 mm 4.4 - 107 - 20 - 28 -
25 140 143 3.9 3.2 106 106 - - 22 -
26 134 137 5.1 5.6 106 105 22 27 28 39
28 140 138 4.8 4.2 101 105 24 23 20 59
29 135 138 6.4* 4.8 99 103 - 21 28 34
31 130 143 3.7 4.3 100 105 24 24 24 20
32 138 138 4.5 4.4 103 100 23 24 29 19
33 147 138 4.3 4.6 110 102 19 19 51 19
34 139 143 4.2 3.7 103 104 27 23 39 27
35 135 135 3.8 6.5* 104 97 24 - 33 34
36 135 139 4.3 3.6 103 103 21 25 33 17
37 143 143 5.0 4.2 99 103 23 24 34 28
38 140 143 4.6 5.8 106 107 18 22 45 40
39 143 140 4.1 3.6 100 99 23 21 41 21
M> 145 - 5.8 - 103 mm 25 - 4L -











Day Day Day Day Day
• i a iifiu tmmnwU . ■■■ \tmm
I 1 1 k 1
Day Day Day Day Day
12 1 k 1
1 0.84 1.6 0.5 1.4 1.2 4.6 5.0 10.6 11.7 3.6
2 1.6 1.1 1.5 1.4 1.5 0.8 1.4 4.7 5.1 5.5
3 2.0 1.9 1.5 2.6 3.6 3.2 2.0 10.7 23.3 29.0
7 1.0 1.0 0.7 1.8 0.8 2.3 1.3 3.6 3.2 2.6
8 2.3 1.7 4.4 2.1 5.9 7.3 6.7 4.3
10 0.3 0.4 0.3 0.07 0.2 1.6 1.9 3.2 1.4 1.1
11 0.25 0.2 0.4 0.12 0.4 1.1 0.6 1.0 1.0 1.4
12 0.8 1.5 1.1 1.4 1.8 5.7 3.3 5.5 9.0 7.9
13 4.6 5.6 5.7 6.2 2.4 5.0 6.0 9.5 15.2 10.0
14 0.13 0.84 0.9 0.7 0.5 1.5 2.1 1.1 1.2 1.1
15 1.5 1.1 1.1 1.6 1.4 5.5 5.9 11.7 14.4 8.7
16 0.41 0.35 0.53 0.34 0.44 0.9 0.09 0.8 0.8 0.9
17 1.1 1.1 1.5 0.8 1.2 3.5 5.0 3.5 8.0 4.4
18 0.6 0.76 1.1 0.34 1.25 3.3 5.1 3.6 4.4 4.4
19 2.6 3.9 4.2 2.4 2.9 4.0 6.3 10.5 6.7 5.2
20 0.6 1.4 2.5 1.2 0.7 1.9 3.8 4.3 4.6 5.2
21 0.32 0.22 0.25 0.2 0.4 0.62 0.52 0.44 2.0 0.93
(Continued)





































23 0,55 1.3 2.5 0.6 0.85 5.1 3.7 5.0 6.0 5.7
24 1.0 0.5 1.3 0.8 1.0 2.5 2.3 3.9 4.0 2.4
25 - 1.4 2.5 2.5 1.6 - 1.2 4.8 4.8 5.9
28 1.9 1.9 1.9 2.59 2.2 4.0 8.6 5.6 16.0 4.0
29 1.2 1.6 1.4 2.5 3.7 9.0 7.1 16.2 46.5 26.0
31 1.3 1.0 0.8 1.1 0.8 3.9 1.5 1.5 1.1 1.2
32 0.38 0.92 1.0 0.8 0.4 3.6 3.0 7.3 5.8 1.7
33 0.3 0.4 0.3 0.1 0.4 1.0 1.4 1.8 2.1 1.6
34 1.0 0.91 0.55 1.4 0.49 0.93 0.73 5.2 11.5 2.5
35 0.9 0.8 0.8 1.9 0.57 3.9 4.2 3.4 5.2 4.9
36 0.44 0.7 0.97 0.56 0.51 3.8 3.27 1.08 4.0 1-56
37 0.5 0.32 0.16 0.32 0.43 1.24 0.95 1.12 1.16 1.1
38 3.9 2.1 4.7 3.4 2.2 5.4 5.9 8.6 7.5 6.0
39 1.35 0.9 2.1 1.3 1.4 3.7 2.1 5.2 9.3 2.8
40 3.6 2.2 3.1 2.7 2.6 3.8 8.4 13.5 33.1 8.3
U 0.81 1.5 2.3 2.8 2.1 8.4 7.5 12.8 8.4 7.6






Day 1 Day 2 Day 3 Day 4
Total 17-hydroxycorticoids
mg./24 hours
Day 1 Day 2 Day 3 Day 4
3 0.7 2.5 1.95 1.43 2.0 9.5 16.0 14.6
4 0.6 0.9* 1.1 1.5** 2.7 6.1* 10.4 11.3**
5 2.0 2.6 2.2 3.4 0.97 11.4 15.4 14.7
6 0.5 1.2 2.7 2.3 1.8 9.1 22.2 23.0
7 0.36 0.66 0.81 1.4 1.1 1.2 2.0 10.8
8 0.5 0.7 2.1 2.1 4.6 12.9 26.2 40.0
9 0.3 0.35 0.68 1.7 3.6 3.5 8.2 23.0
10 0.31 0.34 0.54 1.5 1.38 2.0 7.6 14.6
11 1.6 2.2 3.0 3.9 6.5 12.6 24.7 37.9
12 0.45 1.2 1.7 3.1 1.3 8.3 20.8 34.6
13 2.2 5.2 5.3 6.1 8.1 43.4 32.8 42.0
14 0.16 0.46 1.1 1.75 0.43 2.25 4.0 11.8
15 0.69 1.3 1.26 3.4 2.4 10.3 16.0 28.8
16 1.5 1.9 3.4 2.6 3.6 11.5 11.0 18.1
17 0.4 1.3 2.5 2.6 2.6 9.7 16.2 33.4
18 1.6 2.6 3.7 4.6 5.6 18.1 30.1 49.8
19 0.48 0.74 1.0 1.12 3.0 14.2 16.5 9.1
20 0.22 0.28 1.9 2.1 0.81 2.8 7.9 18.0
21 3.3 5.1 5.4 7.4 10.3 20.2 24.6 28.6
22 2.1 3.0 4.0 5.2 4.8 27.6 25.2 29.3
23 0.21 0.52 0.96 1.0 0.9 3.66 5.5 9.0
24 0.6 2.3 1.4 3.4 4.8 21.5 17.2 20.1
25 0.4 0.6 0.2 0.6 4.3 5.9 10.9 15.0
26 0.86 4.9 3.9 4.1 13.8 23.7 40.7 18.5
27 3.3 5.4 6.1 5.8 4.5 11.2 13.2 13.0
28 1.0 1.8 1.4 3.0 3.4 8.3 9.5 14.1
29 0.33 0.52 0.72 0.26 1.5 4.45 5.25 3.85
* 56 ml. missing.




Patient Sodium Potassium Chloride T.C0c Blood urea
(m.Eq./L.) (mg,d00 ml.)
Pre Post Pre Post Pre Post Pre Post Pre Post
3 139 143 6.0* 4.2 104 103 22 22 20 16
5 140 154 3.6 4.4 107 110 24 25 21 15
6 137 138 4.3 4.7 108 105 23 21 20 19
8 140 140 4.6 4.0 107 106 23 22 34 23
10 138 146 4.7 4.6 106 110 21 24 27 19
11 135 138 4.4 4.0 101 99 20 22 22 18
12 141 143 3.8 3.4 104 107 22 33 31 28
13 140 138 5.0 3.6 109 104 - 16 -
14 142 143 5.1 4.4 101 107 21 22 27 27
15 136 139 4.5 4.3 102 102 22 21 51 33
16 142 143 4.8 4.1 106 105 22 24 23 24
17 136 142 4.6 3.5 107 104 22 23 34 21
18 134 135 3.8 3.8 103 104 23 18 28 30
19 138 138 4.8 5.1 101 103 22 23 44 24
20 138 150 4.1 5.0 105 110 29 26 46 30
21 139 143 4.3 3.8 102 105 25 24 27 22
23 140 144 4.7 4.3 102 102 - 27 34 27
24 138 138 4.9 3.6 105 104 25 25 21 21
25 140 140 5.9 5.1 102 103 18 21 22 24
26 142 143 3.9 3.3 102 104 16 27 21 18
27 139 142 4.9* 4.0 99 103 21 24 20 15
28 00I—ICOSSH 4.4 3.7 106 108 27 25 26 29


























3 0.59 0.61 0.71 1.16 — 2.3 2.0 1.96 4.0 cm
4 1.2 0.9 0.9 0.7 0.7 2.7 2.3 1.1 4.5 2.4
5 1.5 1.3 2.1 2.7 3.4 0.81 0.86 0.55 1.1 1.0
6 0.8 0.5 0.6* 0.6 0.5 1.7 1.5 3.3* 6.8 2.5
7 - 0.29 0.17 - - - 1.26 0.97 - -
8 0.5 0.5 0.6 0.9 0.9 3.4 4.6 5.5 18.5 6.1
9 0.39 0.61 0.24 0.52 0.31 3.9 2.9 1.3 - 1.0
10 1.4 0.43 0.46 0.52 0.17 1.6 1.32 1.9 3.1 1.3
11 1.6 2.0 1.4 2.7 3.2 8.1 5.5 9.5 9.6 8.1
13 3.5 3.0 2.0 2.0 3.0 11.8 12.7 9.9 9.2 14.0
14 0.63 0.6 0.42 0.48 0.31 3.4 1.9 0.54 1.14 0.43
15 0.4 0.98 1.2 1.4 0.54 2.2 3.1 2.9 4.7 2.4
16 1.8 1.9 1.0** 1.7 0.9 3.2 4.2 3.6** 4.2 2.5
17 0.82 0.38 0.57 0.34 0.32 1.3 1.05 2.8 2.64 2.36
18 0.5 0.7 1.3 2.0 1.3 4.6 4.7 7.6 13.3 8.6
19 0.5 0.3 0.7 1.1 0.4 1.8 1.8 5.2 2.4 2.5
20 0.7 0.7 0.6 0.2 1.3 1.1 1.1 0.8 0.8™*
21 2.4 2.3 3.0 2.4 2.9 6.7 4.0 7.7 8.6 4.1
22 2.8 1.8 2.6 4.4 2.9 6.5 5.5 9.1 11.1 5.5
23 0.55 0.78 0.43 0.33 0.23 1.26 0.92 1.52 2.32 1.0
24 - 0.8 1.3 1.4 0.5 cm 3.0 7.1 9.7 4.5
25 0.2 0.3 0.4 0.5 0.2 0.6 0.7 1.8 2.2 0.6
27 3.2 5.4 2.7 5.6 2.1 3.0 4.1 5.1 10.4 3.2
28 1.4 1.5 1.0 0.5 1.0 3.1 8.2 7.2 10.2 4.7
29 0.04 0.07 0.13 0.2 0.24 0.48 0.97 1.16 1.79 0.3
* Approximately 90 ml* lost.
** Approximately 45 ml. lost.




The determination of the amount of I which is bound to
serum protein is generally accepted as an index of the amount of
circulating thyroid hormone provided that iodine compounds have
not been recently ingested, applied to the skin, or employed in
contrast media for radiological purposes (e.g. Danowski et al.,
1950; Start et al., 1950).
Wayne (i960) confirmed Praser's view (1956) that the test is
of diagnostic value in adult patients with suspected mild
hypothyroidism. According to Wilkins (1957) and Andersen (1961)
the estimation of the serum protein-bound iodine (P.B.I.), or
preferably the butanol-extractable iodine (B.I.I.) is the best
single criterion of thyroid function which is currently available
in paediatric practice.
Many workers (e.g. de Mowbray and Tickner, 1952; Macgregor
and Wayne, 1958; and Wayne, i960) have experienced serious
technical difficulty with several methods but this is chiefly due
to the problem of contamination. Although Macgregor and Farrell
127(1958) estimated the P.B. I. in ei^ity-two hypothyroid patients
and found that only nine had values greater than 3.0/tg./lQO ml.,
the normal accepted range is usually taken as 3.5 • 7.0/^g./lOO ml.
(Fraser, 1956). The limits vary slightly with the methods
employed and with the laboratory which performs the test, thus the
64*.
normal range for P.B.I, determination reported in this study,
using the method of Grossmann and Grossmann (1955)» is
3.3 - 7.4jJg./l00 ml. (Yfillcox, 1962). There is no sharp
delineation between normal and abnormal values and the
significance of this will be discussed later.
Studies of serum protein-bound iodine in adults are not
applicable to children. In 1925, Cooper reviewed the histological
appearance of the thyroid gland at various ages and she
interpreted her findings in childhood and adolescence as being
compatible with hyperactivity. Evidence has been presented that
the "thyroid secretion rate" is greater in young animals than in
adults of the same species (Hurst and Turner, 1947| Maqsood, 1950,
Wilansky, Hewshaw.and Hoffman, 1955)•
Danowski et al. (1951) have shown that within twelve hours of
birth the level of serum protein-bound iodine in the infant is
similar to that of the mother during pregnancy or within a few
hours of delivery. During the first week of life there occurs a
transient but statistically significant increase in the mean value
of the iodine fraction. Prom the sixth to the twelfth week the
level of the protein-bound iodine falls below that of the neonate
but, until the age of one year, the average value remains higher
than that in older children and in the euthyroid, non-pregnant
adult.
Danowski et al. (1952) also found lower concentration of
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protein-bound iodine in early adolescence in the diabetic and
non-diabetic subject. This confirmed the work of Shock (1944) but
was not consistent with the widely accepted concept of
"physiological hyperthyroidism" at puberty. Since then Oliner
et al. (1957) have established normal standards in children for
■^1 uptake and P.B.^T. They concluded that the thyroid gland
in children up to the age of four years and possibly later, is
normally in a state of hyperactivity when compared with the
euthyroid adult.
Blood samples for P.B.I, determination may be withdrawn at
any time of day and the level is unaffected by relation to meals,
fever, physical aotivity or any other variable which distorts the
basal metabolic rate (Wolman, 1957). In healthy young adults,
Danowski et al. (1949) stated that the level of the protein-bound
iodine appeared relatively constant over a period of weeks.
All the determinations in this series were carried out in
duplicate, on venous blood. Those tests which were abnormal were
repeated on another day, and patients with a low value on two
separate occasions were investigated using ^2j, vhere this was
practicable.
The results of the serum protein-bound iodine estimations





Patient Serum protein-bound iodine
Mfc./lOO ml.


































































The determination of the Basal Metabolic Rate (B.M.R.), once
widely relied upon as the principal test of thyroid function, is
now seldom used by some clinics in the diagnosis of hypothyroidism
(Wilkins, 1957; Andersen, 1961). However, according to Heald
(1962), the B.M.R. is still used with surprising frequency,
although more precise methods of assessing thyroid function have
been available during the past fifteen years. The Basal Metabolic
Rate is not a direct measure of thyroid activity, therefore the
results of such investigations must be interpreted with caution.
From the stand-point of diagnosis in the adult, Hortling and
Hiisi-Brummer (1959) found determination of B.M.R. and serum
protein-bound iodine of almost equal value in 535 patients. Again,
in the adult, using the reference standards of Robertson and Reid
(1952), Wayne (i960) found that the B.M.R. agreed with the final
diagnosis in 77% of cases of hypothyroidism.
Reports in the paediatric literature are not so encouraging,
mainly because the determination of B.M.R. in children is
complicated by factors not encountered in adults. Technical
difficulties frequently arise from the failure to attain
satisfactoxy basal conditions and the selection of the most
physiological standard remains controversial (e.g. Talbot, 1936;
Talbot, Stewart and Broughton, 1938? Kleiber, 1947; Eichorn,
69#
1955)# Behrendt (1949), in a most competent discussion of Basal
Metabolic Rate, stated "that for the success and reliability of
the B.M.R. test in children over six, the ability to handle
children is of far greater importance than technical skill."
Performance of Tests
The B.M.R. was determined by the method described by Behrendt
(1949), using the British "Benedict" Portable Metabolism Machine.
Some children were allowed their usual diet up to fourteen hours
before the test, and thereafter they were fasted until completion
of the investigation; others were given a light breakfast of
cornflakes and milk at 6 a.m. at the discretion of the Ward
Sister. In our experience this ensured more basal conditions,
particularly in young children who were apt to become resentful
and restless if deprived of a meal in the presence of others.
B.M.R. determinations, with and without this light breakfast,
showed no significant difference in the same child (Clayton, 1962).
The age, height and weight of the patient were noted. On the day
before the test, it was the practice of the person carrying out
the determination to explain the procedure to the child and to
make him familiar with the apparatus. All investigations were
repeated, usually on successive days.
Calculation:
The barometric pressure and barometer temperature were read
7c.
on completion of the trace. A line was drawn through the base of
the respiratory tracings, using the longest flat portion. The
number of cubic centimetres of oxygen consumed per minute was
then calculated. The day barometric pressure was obtained by
subtracting the brass scale correction, and the water vapour
pressure at average temperature during the test period, from the
barometric reading (tables: Harrison, 1949). Using the day-
barometric pressure the oxygen volume was corrected to N.T.P.
Where the assumed respiratory quotient is 0.83, the value obtained
was converted to Calories per hour using the following formula:-
Volume of oxygen consumed per ^ , o?t-
minute at N.T.P. (c.c.) ± QQQ *#°°
The child's surface area was then calculated from a nomogram
(Dubois, 1936), and "Total Calories per Hour" was corrected to
"Total Calories per Hour per Square Metre of Body Surface".





Patient Calories per Hour per Square Metre
Age
Percentage of Normal fort
Weight Height Surface Area
2 88 85 90 87
3 110 98.5 101 101
13 116 115 119 116
18 124 108 109 109
19 68 64 84 73
39 94 76 82 79
40 72 67 78 74
BASAL METABOLIC RATE
GIRLS
Patient Calories per Hour per Square Metre
Age
Percentage of Normal for;
Weight Height Surface Area
5 89 76 72 76
18 68 59 72 64
21 106 98 . 91 95
24 103 88 82 84
27 133 99 110 102
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STUDIES OF THYROID UPTAKE OF 132I0DINE
132
The uptake of Iodine by the thyroid after the oral
administration of 5/*<>» was studied at intervals for six and a
half hours in certain patients.
When the uptakes were poor, the patients were tested again
after three days' treatment with thyrotropic hormone 5 units
daily, intramuscularly (Armour Laboratories Ltd.).
The results are given in Table 26.
Table 26.
STUDIES OF THYROID UPTAKE OF 132I0DINE
Patient No. 7 (female):
"Neck uptake" 17*3^ at l*r hours.
25.5$ at 3i hours.
15.8$ at 6 hours.
Comment: Normal (the six hour uptake is probably inaccurate)
Patient No, 19 (male):
"Neck uptake" before T.S.H. at 2^ hours
8.8% at 4 hours.
6.4/' at 63 hours
"Neck uptake" after T.S.H. 9.1% at 2 hours.
$•CO at 4g hours
6.8% at 63 hours
Comment: Primary hypothyroidism.
Patient No. 29 (male):
"Neck uptake"
No response after T.S.H.
Comment: Primary hypothyroidism.
Continued.
8.5$ at 2 hours.
7*5$ at 4 hours.
4.5$ at 6| hours.
(Table 26, continued) 74.
Patient Ko. 32 (male):
"Neck uptake" 24.1$ at 2 hours.
26.0$ at 4 hours.
34.9$ at 6j hours.
Comment: Normal thyroid uptake.
Patient No. 34 (male):
"Neck uptake" before T.S.H. 14.4$ at hours.
15.9$ at 6 hours.
"Neck uptake" after T.S.H. 15.4$ at 4 hours.
13.3$ at 6|r hours.
Comment: No change after T.S.H. The "neck uptakes" are probably
down below the normal range (moire than 15-18% at 6 hours) but they
are not extremely low.
75.
DISCUSSION
In children, as in adults, the most important aspect of
clinical medicine is diagnosis and the pathologist, like the
physician, should evaluate his laboratory findings against the
background of a carefully taken history and examination. The
interpretation of the history in paediatric practice involves
some assessment of the informant as a witness (Ellis, 1960) and
although the chief complaint is of value, sometimes it can be very
misleading.
Thus, in this series of investigations on seventy children,
forty-two were brought to hospital because of "small size", or of
"small size" in association with some other complaint
(e.g. convulsions). However, sixty-four were found to be below
the third percentile for height, including two girls whose
measurements are not tested but who were well below this rating.
In some instances no mention of shortness of stature was made by
the informantj of greater importance, small size was not
infrequently overlooked by experienced clinicians. The physical
examination of the child is incomplete without the determination of
height and weight but these values would be of greater
significance if plotted on standard charts (e.g. Tanner, 1958),




















































There was no significant relationship between the incidence
of abnormal pregnancy and confinement and dwarfism.
Birth Weight.
The birth weights of boys and girls are shown on the
accompanying histograms.* There is a suggestion of two distinct
groups in both sexes. The mean birth weight for boys was
6 lb, 4 02. £ S.D. 1 lb. 11 02., and that for girls was
5 lb. 13y 02. +_ S.D. 1 lb, 10 02. These are significantly lower
than the normal values obtained in the Oxford Survey (Lancet,April,
1955), where the mean birth weight for 298 boys was 7.83 Ik. £
S.D. 1.08 lb., and that for 282 girls was 7.31 lk. + S.D. 1.06 lb.
Although most of the children in this study were born in the
South-Eastern area of England, the Oxford values were chosen for
comparison in preference to those of Falkner for London children
(1958). Falkner did not include standard deviations in his paper,
but his mean values of 7.8 lb. for bqys and 7.1 lb. for girls
show a good correlation with those of the Oxford Survey.
Birth Order and Maternal Age.
The analysis of birth order and maternal age by comparison
* Figs. 2 and 3«
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with non-affected siblings is only satisfactory where the family
is complete (Carter, 1962), and this analysis could not be
undertaken because most of the families in this study are
incomplete. The alternative method of testing maternal age and
birth order effects, which makes use of all the index cases, is
to compare maternal age and birth order of each index case with
that of births in the same year in the general population.
Accurate details of live and still-births could not be obtained,
therefore this method of analysis was not attempted.
Sex Ratio.
Of seventy children studied, thirty-six boys and twenty-six
girls were on or below the third percentile for height against
chronological age. This gave a sex ratio of 0.72.
Consanguinity.
None of the parents were blood relatives.
Twins.
There was one index case with twins (girl no, 22), She was
the smaller and only survivor of the twin pair.
Triplets.
Boy no, 35 was the smallest and sole survivor of triplets.
Parental Heights.
The parental heights of the children studied were as
follows:-
Boys: Maternal height 63,3 inches +_ S.D. 2.7 inches.
Paternal height 67,7 inches +_ S.D. 3.8 inches.
Girls: Maternal height 61.6 inches +_ S.D. 2.1 inches.
Paternal height 66.8 inches £ S.D. 3.45 inches.
Parental heights were compared with values published by
Tanner, Healy, Lockhart, MacKenzie and Whitehouse (1956). These
were:-
Males: 67.5 inches £ S.D. 2.56 inches.
Females: 63.2 inches +_ S.D. 2.24 inches.
For the purpose of comparison these values were corrected
from millimetres to inches and corrected from supine to standing
(1932).
height by means of Palmer's Tables They agree closely with the
unpublished data of Tanner and Whitehouse (1962):-
Males 68 inches, females 63 inches.
81.
No significant difference was apparent between those figures
for the children under study and normal values.
Age at which "Small Size" was First Noted.
At birth, prospective dwarfs are indistinguishable from
other newborn infants in the population at large. Growth
continues normally throughout infancy to above two to three
years (Martin and Wilkins, 195B), and Seckel (i960) has stated
that dwarf growth manifests itself between one and three years or
later, but these statements are not confirmed by the present
study. Twenty out of forty-one boys and sixteen out of
twenty-nine girls were found to be of small size or showed
slowing of growth within the first year of life.
In eighteen of the seventy children studied the final
diagnosis was as follows:-
Boys: Patient Final Diagnosis
2 Cyst of Rathke1s pouch























Evidence of hypopituitarism; at thirtieth
percentile for height against chronological
age.
Chronic regional ileitis.













Of the remainder who had a complete endocrine investigation,
the following groups emerge:-
BOYS
Group A: Patient no. 3.
Normal thyroid function, normal adrenocortical response to ACTH
good response to "Metopiron", normal insulin tolerance.
Group B: Patients 7, 9, 10, 11, 12, 16, 18, 33.
Normal thyroid function, subnormal adrenocortical response to
ACTH, impaired or absent response to "Setopiron", abnormal
insulin tolerance.
Group C: Patient no, 21.
Normal thyroid function, subnormal adrenocortical response to
ACTH, good response to "Metopiron", abnormal insulin tolerance.
Group D: Patients 23, 24, 31, 28, 36, 41.
Normal thyroid function, normal adrenocortical response to ACTH
impaired or absent response to "Metopiron", abnormal insulin
tolerance.
Group E: Patient no. 19.
Impaired thyroid function, normal adrenocortical response to




Group W: Patients 6, 8, 17.
Normal thyroid function, normal adrenocortical response to ACTH,
good response to "Metopiron", abnormal insulin tolerance.
Group X: Patients 4, 5, 14* 16, 20, 23, 28.
Normal thyroid function, subnormal response to ACTH, impaired or
absent response to "Metopiron", abnormal insulin tolerance.
Group_Yi Patients 10, 19, 25, 27«
Normal thyroid function, subnormal adrenocortical response to
ACTH, good response to "Metopiron", abnormal insulin tolerance.
Group Z: Patients 15, 21, 22.
Normal thyroid function, normal adrenocortical response to ACTH,
impaired or absent response to "Metopiron", abnormal insulin
tolerance.
Each group was examined in relation to certain physical
attributes, as follows:-









COMPARISON OF MEAN GROUP VALUE WITH NORMAL VALUES
(Where N a normal value)
Group "P"
NA 0.5 - 0.6
KB ^ 0.01*
NC 0.5 - 0.6
ND 0.1 - 0.2










* Indicates "P" values of possible significance.
< = less than.
COMPARISON OF MEAN GROUP VALUE WITH NORMAL VALUES
(Where N = normal value)
Group "P"












COMPARISON OF MEAN GROUP VALUE WITH NORMAL VALUE
(Where N = normal value)
Group WP"
NA 0.1 - 0.2
NB > 0.9
NC 0.05 - 0.1
NO >0.9
NE 0.1 "* 0.2
* Indicates "P" values of possible significance.
> = greater than.












XY 0.02 - 0.05*
COMPARISON OF MEAN CROUP VALUE WITH NORMAL VALUE




NW 0.4 - 0.5
NX vo«01UN,O
NY ^ 0.01*
NZ 0.7 - 0.8









COMPARISON OF MEAN GROUP VALUE WITH NORMAL VALUES
(Where N a normal value)
Croup •tptf
NA 0.8 * 0.9
NB «*>.01CM•O
NC 0.5 - 0,6












XZ 0.02 - 0.05*
(Only one value in Group z)
COMPARISON OF MEAN GROUP VALUE WITH NORMAL VALUE
(Where N = normal value)
Group "P"
NW < 0.01*
NX 0.05 - 0.1
NY ^ 0.9
NZ 0.05 - 0.1
(Only one value in Group z)
Height Percentile Rating for Skeletal Age.
No significant difference was found on examining the
percentile rating for height against skeletal age between groups.
All standard deviations and probabilities are based on the
assumption that there is a symmetrical distribution, i.e. no
skew.
* Indicates "P" values of possible significance.
= less than, > = greater than.
All standard deviations are £ the value given*
Only MP" values around 0,05 are tabulated. A "P" value of
below 0.05 suggests a significant difference between two groups
but the numbers involved in this study are so small that no
conclusive results can be reached.
Of seventy children studied, eighteen showed evidence of a
primary disease process initially correlated to the anterior
pituitary gland. The endocrine status of thirty-four of the
remainder was evaluated as completely as possible, and five of
these children (boy no. 21} girls 10, 19, 25 and 27) showed
varying degrees of primary adrenal insufficiency. Twenty-nine
children had biochemical evidence of hypopituitarism and none of
these showed signs of a destructive lesion. However, it is
possible that symptoms and signs of a specific process may become
apparent at a later date,
A number of instances of dwarfism have been reported in
which there was no suggestion of a destructive lesion of the
pituitary gland and these have been referred to as dwarfs of the
Lorain-Levy type, in contradistinction to the primordial Dwarfs.
It has already been stated in the introduction to this thesis
that such classifications on purely clinical grounds may be
incorrect and potentially dangerous. For example, half of the
thirty-four children under discussion showed varying degrees of
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adrenal insufficiency, and two beys (nos, 9 and 16) showed no
response to a standard ACTH test on the absence of olinieal signs.
Another boy (no. 26) collapsed and died during a lumbar air-
encephalogram j he had shown a very poor response to ACTH and
biochemical evidence of hypopituitarism was confirmed at autopsy.
It is possible that hypopituitarism may exist in the absence
of a destructive process affecting the anterior lobe, and that a
condition may exist in the human which is comparable to that in
the dwarf silver mouse (Smith and MacDowell, 1930, 1931)• This
condition in mice is attributed to the hereditory absence of
eosinophil cells in the hypophysis and a few autopsy reports on
pituitary dwarfs support this possibility (Kraus, 1926),
Single hormonal deficiencies of the anterior pituitary have
been described in children (Cleveland, Green and Migeon, i960)
but such claims are scarcely valid in the absence of a
sensitive assay for Human Growth Hormone, and in the absence of
further support of Fitschen's claim (1962) to have detected
urinary gonadotrophin activity in apparently normal children.
It is tempting to attribute the findings of dwarfism,
retarded skeletal age and abnormal insulin tolerance in girls
6, 6 and 17 to a pure Growth Hormone deficiency, but boy no, 3
showed no biochemical abnormality and yet he was dwarfed and his
skeletal age was considerably retarded. The findings in this boy
suggest deficiency of a "bone-age" hormone perhaps related to
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Growth Hormone, as MSH is related to ACTH. Further chemical
studies on the Growth Hormone molecule may confirm this
possibility in view of the isolation of an active small molecular
weight compound from the larger ACTH molecule, and the separation
of an insulin-like factor from Growth Hormone (Ottaway and Paul,
1957; Huggins and Ottaway, i960).
Boy no. 22 and girl no. 11 showed no biochemical evidence of
hypothyroidism on determination of basal metabolic rate and serum
protein-bound iodine, but there were clinioal signs of hypo-
132
thyroidism in both children. I could not be carried out.
Thyroid function often diminishes more slowly in hypopituitarism
than in primary thyroid disease (Wayne, i960). It is, therefore,
not surprising that these tests have given inconclusive results.
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In bpy no. 19 I studies were consistent with a diagnosis
of primary hypothyroidism but these were at variance with the
clinioal findings, particularly as this child was very alert
mentally. In addition, he did not show the large increase in
urinary total 17-hydroxycortieoids after "Metopiron" which was
evident in those children with an unequivocal diagnosis of
primary hypothyroidism (girl no. 18j boys 29, 34 and 40). The
reason for this is not known.
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PROVISIONAL CLASSIFICATION OF HYPQPITUITARY
DVZABPISM IN PRE-PUBERTAL CHILDREN
The diagnosis of hypopituitaiy dwarfism in pre-pubertal
children is difficult and this has been stressed by many authors
including Martin and Wilkins (1958) and Wilkins (1957), but the
findings in this thesis indicate that treatment cannot be delayed
until a conclusive diagnosis is established after puberty. This
statement is particularly applicable to those children who present
with adrenal insufficiency where the defect may be remediable by
the administration of ACTH or cortisone.
The increasing availability of Human Growth Hormone provides
a non-androgenic anabolic agent of established potency. Although
no conclusive results for long-term therapy are available in the
four boys studied (nos, 12, 24, 31 and 33), preliminary findings
suggest that this hormone effects an increase in height and muscle
mass when given in adequate dosage (e.g. 25 mg. by intramuscular
injections twice weekly).
The choice of therapeutic agent is dependent on the diagnosis
and a provisional classification of hypopituitapy dwarfism in
pre-pubertal children is suggested for research purposes. This is
based on the findings in the thirty-seven children who had a
complete endocrine investigation using standard tests.
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Group I Normal thyroid function
Normal adrenocortical response to ACSH
Normal response to "Metopiron"
Normal insulin tolerance
Retarded skeletal age
Group II Normal thyroid function
Normal adrenocortical response to ACTH
Normal response to "Metopiron"
Abnormal insulin tolerance
Retarded skeletal age
Group III Normal thyroid function
Impaired adrenocortical response to ACTH
Impaired response to "Metopiron"
Abnormal insulin tolerance
Retarded skeletal age
Group IV Normal thyroid function
Impaired adrenocortical response to ACTH




Group Y Normal thyroid function
Normal adrenocortical response to ACTH
Impaired response to "Metopiron"
Abnormal insulin tolerance
Retarded skeletal age
Group VI Abnormal thyroid function
Normal adrenocortical response to ACTH
Impaired response to "Metopiron"
Abnormal insulin tolerance
Retarded skeletal age
It is plain that this attempt at classification is Incomplete
because of the small numbers of children involved, and the
absence of a sensitive assay for Human Growth Hormone and of
detailed studies of urinary gonadotrophin using a sensitive method
like that of Fitschen (1962). Consideration of these parameters in
diagnosis is therefore precluded.
Group IV would appear to consist of those dwarfs with primary
adrenal deficiency, but this condition is not usually associated
with dwarfism. It was considered desirable to include this group




The frequency and severity of insulin sensitivity in children
of short stature prompted investigation of the occurrence of
hypoglyoaemic convulsions in these children (Renwiek, 1962).
Hypopituitarism as a cause of hypoglycaeraia is said to be rare,
and in their study of twenty-six cases of pituitary dwarfism,
Martin and Wilkins (1958) described two patients who had
hypoglycaemic episodes in early childhood but in whom the
convulsions had resolved spontaneously.
It is the author's experience that hypoglycaemia is frequently
not considered in the differential diagnosis of a child with
convulsions and the condition is sometimes overlooked. A
retrospective diagnosis of hypoglycaemia may be difficult or
impossible to establish.
Twelve children in the present study had a history of fits
and of these, one was found to have a craniopharyngioma (boy no.30).
In ten of the remaining patients no organic cause could be found
for their convulsions, but all of them were below the third
percentile for height. The last patient was small, but not
dwarfed (boy no. 17)* Most of the children had fits between the
ages of six months and five years, and in some the convulsions
appeared to become less frequent or to disappear completely.
Ten children had fits in the morning before breakfast, or at
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a time when their appetite was poor, and they were "off their
food". Two children, boy no. 21 and girl no. 20, had fasting
blood sugars below 50 mg./lOO ml; the remainder were in the
normal or low normal range. It should be indicated that these
determinations were done by the modified method of Folin and !u
(Wilkinson, I960) and the values are about 10-15 mg./lOO ml.
higher than true blood glucose estimated by glucose oxidase.
All of the children were markedly sensitive to a "half" dose
of insulin on testing and all of them showed a decreased capacity
to correct this insulin induced hypoglycaemia. An exception was
found in girl no. 28, who was sensitive to a"half-dose" of insulin
but who later showed a normal response to a"full' dose.
Eight of the twelve children who had a complete set of
endocrine investigations could be grouped as follows:-
Girls 10, 25, 27; Normal thyroid function, abnormal
and boy 21 adrenocortical response to ACTH, good
response to "Metopiron", abnormal
insulin tolerance.
Girls 20, 28; Normal thyroid function, abnormal
and boy 17 adrenocortical response to ACTH,




Boy 31 Normal thyroid function, normal
adrenocortical response to ACTH,
absent response to "Metopiron",
abnormal insulin tolerance.
Patient no. 26, a dwarfed boy v/ith a history of
hypoglycaemic convulsions could not be fully investigated, but he
showed a very poor response to exogenous ACTH during a standard
test. This child died suddenly during air-studies and at autopsy
the main endocrine findings were pancreatic hypoplasia, and
atrophy of the zona reticularis and zona fasciculate. The
pituitary was normal on macroscopic examination. Another child
(girl no. 7)» who was not fully investigated, also had a very poor
response to ACTH.
It may be concluded that four children who were under the
third percentile for height and who had a history of fits, showed
primary adrenal insufficiency (girls nos. 10, 25, and 27j boy
no. 21), It is of interest that a sibling of boy no. 21 died
during the second stage of labour and at autopsy no adrenal tissue
was found.
Two girls (nos. 20 and 28) and one boy (no. 17) were
considered to be deficient in ACTH, and boy no. 31 showed no
response to "Metopiron" but he had a good response to ACTH. Again,
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it should be pointed out that girl no. 28 had a sibling of five
and a half weeks who was admitted to another hospital because of
feeding difficulty and convulsions.
It was possible that some of these children may have had a
deficiency of Growth Hormone in addition to these endocrine
abnormalities•
The hypophysectomised human, in common with hypophysectomised
animals, is unable to withstand prolonged fasts and is profoundly
sensitive to insulin. Boy no. 2 provides an illustration of this,
(see Fig. 4).
Patient No. 2.cf 12 yrs.
INSULIN TOLERANCE BEFORE AND AFTER
HYPOPHYSECTOMY




An insulin tolerance test before operation revealed a marked
sensitivity to insulin and a failure of the blood sugar level to
return to fasting values. Six months after hypophysectomy and the
removal of a cyst of Ratlike' s Pouch, the degree of insulin
sensitivity and hypoglycaemia unresponsiveness was more striking.
The use of C-14 labelled glucose has increased the
understanding of insulin sensitivity in animals and this has been
shown to be due to two factors in the hypophysectooised dog (Wall,
Steele, De Bodo and Altszuler, 1957j Altszuler, Steele, Dunn,
Wall and De Bodo, 1959)• These workers found an increase in the
rate of removal of plasma glucose in the hypophysectomised dog and
this resulted in a fall of plasma glucose below normal levels. The
flow of glucose from the liver into the plasma in response to an
insulin-induced hypoglycaemia was not increased in the
hypophysectomised dog and this resulted in a continuation of the
hypoglycaemic state.
The "anti-insulin" effect of Growth Hormone has been
demonstrated in numerous experiments but the mechanism of action
is unknown. De Bodo and Altszuler (1958) have discussed the
question of whether this represents a direct or indirect
antagonism between Growth Hormone and insulin.
In the present studies, insulin tolerance tests were carried
out before the administration of Human Growth Hormone (M.R.C.
Raben preparation) in boys 12, 24 and 33* The striking feature-
* See Figs. 5» 6 and 7.
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patiexrfc bo, 12, Mais, 12 years
EFFECT OF mMA2I G-SQ\7TH IIQSMOHB Oil
INSULIN SENSITIVITY
Patient No. 12. d* 12 yrs.
EFFECT OF HUMAN GROWTH HORMONE ON
INSULIN SENSITIVITY
Insulin (0.125 units/kg. subcutaneously)




patient no. 24. 1-a.lc, 11 years
EFFECT OF HUMAN G-RQWTH HORMONE 0N
INSULIN SENSITIVITY
Patient No. 24. d" 11 yrs.
EFFECT OF HUMAN GROWTH HORMONE ON
INSULIN SENSITIVITY
Insulin (0.125 units/Kg. subcutaneously)
110 r *
Response after Growth Hormone
Response before Growth Hormone
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patient no. 33° Male. 6 years
EFFECT OF KUijAN flRU'.vSH HOSHOKE Oil
IHSiJLIN SENSITIVITY






EFFECT OF HUMAN GROWTH HORMONE ON
INSULIN SENSITIVITY
Insulin (0.125 units/kg. subcutaneously)
Response after Growth Hormone
Response before Growth Hormone





was the abolition of sensitivity in patients 12 and 24, bat little
change was observed in no. 33. ?he last mentioned child was
shown to have a moderate degree of impairment of adrenocortical
function and this raised the question of whether the action of
growth hormone on carbohydrate metabolism in the human requires an
intact adrenal cortex; but the present studies are incomplete and
too few to provide strong support for this theoiy.
It is widely accepted that the anterior pituitary hormones
which exert the greatest influence on carbohydrate metabolism are
ACTH and Growth Hormone. It is of great significance that ACTH,
Growth Hormone and adrenal corticosteroids increase the output of
glucose by the liver in the post-absorptive state, and that they
also provide a means whereby the liver releases glucose into the
blood stream when the need arises. However, the mechanisms
involved, particularly those concerned with the actions of Growth
Hormone on carbohydrate metabolism, remain uncertain.
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DBTAILS OF SOME PATIENTS WITH A HISTORY OF HYPOG-LYCAEMIA
PATIENT HO. 17:
This six-year old boy was well until two weeks before
admission, when he had diarrhoea associated with central
abdominal colicky pain. He recovered and returned to school. The
following day he passed three large stools and his mother put him
to bed. She returned to find him unconscious; there was no
warning cry. The child had a fixed stare and his body was
twitching. There was no cyanosis. The family doctor gave him
soluble phenobarbitone which stopped the "twitchings" for about
twenty minutes. The child remained unconscious for three hours
and he was incontinent of urine. On admission to hospital the
blood sugar level was 12 mg./lOO ml. Four hours after
intravenous glucose, the blood sugar level was 20 mg./lOO ml.
The child had had very little to eat on the day before this
episode, and he had no breakfast on that morning. There was a
history of a previous fit which occurred at the age of two years,
again before breakfast. At that time he was cyanosed and he
"jerked" for fifteen minutes.
PATIENT HQ. 21}
This boy had "trembling of the limbs" during the first two
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weeks of life. He was treated with sedation and the trembling
gradually disappeared. At the age of nine months the child
began to have convulsions. These usually occurred first thing in
the morning when he suddenly cried out, became floppy, and lost
consciousness. During a fit his eyes rolled and his legs and
arms twitched. The child's mother placed him in a hot bath and
the twitching stopped. He would sleep from one to twelve hours
after a fit. In spite of sedation with phenobarbitone, the child
had an average of two fits a month. He usually did not eat very
well before a fit, and the child's mother came to expect an
attack whenever he wont off his food,
PATIENT NO, 26:
At the age of four months this sixteen-month old boy had one
convulsion which was associated with a high temperature. There
were no further convulsions until fifteen months of age, when he
had another which lasted one hour. At that time "his eyes rolled
and he was out but not unconscious". One fit was observed in
hospital, and a blood sugar taken during the fit was
44 mg./lOO ml. The child made a complete recovery within thirty
minutes of the intravenous administration of 10 ml, of 50%
glucose.
PATIENT HO, 27:
When this boy was two years old, his mother heard a scream
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early one morning and she found the child convulsing and frothing
at the mouth. This fit lasted for more than an hour. He tbs in
perfect health before and after the fit.
Eight months later the child was found unconscious, there
were no convulsions and he responded to intravenous glucose within
two hours. There were no further episodes until the child was
four years old, when his mother was unable to rouse him one
morning. He was limp, and he remained unconscious on that
occasion for three hours. Again he responded to intravenous
glucose.
PATIENT NO. }0t
This boy, aged six years and ten months, was well until a
few months before admission, when he complained of headaches and
fits which ware diagnosed as Petit Mai. They were of short
duration (five to ten seoonds) and sometimes the child had five
or six fits a day, with intervals of half to three quarters of an
hour between each episode. Usually they occurred first thing in
the morning.
During a fit the boy would hold his head still, stare, then
drop his head. This was followed by normal behaviour. He was
incontinent of urine during a fit on three occasions. Treatment
with "Tridione" had no effect.
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PATIENT NO. 31:
This boy was well until he was three years old, when he had
a fit which lasted twenty minutes. The informant described tonic
and olonio spasms and the child was incontinent of urine. Since
that time he had many fits without tonic or clonic spasms and
without urinary incontinence. The fits usually occurred in the
morning, never at school or at play. There was no aura* The
child suddenly fell unconscious on rising. He usually got out of
bed and dropped to the floor where he lay unconscious for a few
minutes, then he went to sleep for three or four hours. He was
usually flushed at the start of a fit, then he went mauve around
the mouth. The child had a fit about evexy three to four months.
PATIENT NO. 7:
This two-year old girl had a history of convulsions from the
age of one year. "She seemed to go stiff, her eyes rolled, she
frothed at the mouth, and she went mauve about the lips". She was
unconscious for varying lengths of time (not stated) and she slept
after each fit. They seemed to increase in frequency and when the
child was seen on admission she had two or three fits a day and
sometimes two or three in the night.
PATIENT NO. 10:
At the age of four and a half years this girl had diarrhoea
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for one week. There was slime and blood in the stools. No other
member of the family was affected. One week after recovery, she
got up in the morning feeling cold and drowsy. Just before lunch
her eyes rolled up, she frothed at the mouth, and first her arms
jerked and then her legs. Her head turned to the left and she was
blue around the mouth. She was unconscious for ten minutes. There
was no incontinence or fever but the child was off her food all
that day. She recovered completely by the following day and she
had no further fits.
PATIENT NO. 20;
This ten-year old girl had a history of "nervous spasms"
which lasted a few seconds during which time she was unable to
speak and she appeared to be terrified. No further details were
given, but the child was found to have fasting blood sugars of
below 50 mg./lOO ml. during a hospital admission,
PATIBNT NO. 25!
This child was seen at the age of sixteen months on account
of convulsions and failure to grow. At the age of eight months
she had a fit in which she stiffened and her eyes rolled back.
She then became very limp. There was no associated fever and she
had no infections at that time. One month later the child had
three or four fits in one day. Between the ages of nine and
eighteen months there were three recorded fits and two of these
occurred when the child's appetite was "very, very poor".
Treatment with phenobarbitone was ineffective.
PATIENT NO. 27:
This girl was first seen at the age of sixteen years on
account of small stature and absence of secondary sex
characteristics. As an infant she would not take her feeds well
and there was a history of "spells" from the age of seven months
to three years. There were about twelve such episodes during
that time and they were most severe at one year of age.
Unfortunately, this child was referred from Cornwall and it was
not possible to obtain a detailed history of these "spells",
which were described by her doctor as "breath-holding" attacks,
PATIENT NO. 28;
When this girl was six months of age she went off her feeds,
and in the middle of one day she had a fit during which her eyes
rolled, her legs curled up, and she was dazed. This fit lasted
half an hour and she slept for hours afterwards. At that time she
had one fit a day for one month, then they gradually became less
frequent. The child was perfectly well between fits, but she
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occasionally vomited during a fit. She also lost weight at that
time.
At the age of six and three quarter years, the child's
mother thought that the patient had tripped and fallen, but she
made no attempt to get up and her mother found her lying stiff,
with her eyes staring. She was not incontinent. ?.'hen she came
to the ohild cried hysterically for about haIf-an-hour. She had
a second fit, which was equally severe, the same evening. The
local doctor treated her with phenobarbitone and penicillin but
she had nine further episodes between that time and her admission
to hospital. The fits had become gradually less severe.
There was also a history of headaches and drowsiness at
school. The child was off-colour for about a week, but she
recovered spontaneously. A younger sibling aged five and a half
weeks also had a history of feeding difficulty and convulsions.
HYPONATRAEMIA
112.
Most patients with lesions of the anterior pituitary gland are
not "salt-losers" (Luetscher and Axelrad, 1954; MacLean, Lipaett,
Ray and Pearson, 1955; Hokfelt, Luft, Ikkos, Olivecrona and
Sekkenes, 1959)» and this is supported by the plasaa sodium values
in the present study. Only three girls had plasma sodium values of
135 m.Eq./L. and below. No. 11, who had biochemical evidence of
impairment of the pituitary-adrenal axis and who showed some
clinical signs of hypothyroidism, had a plasaa sodium level of
135 m.Eq./L. Girl no, 18, with unequivocal evidence of primary
hypothyroidism, had a plasma sodium value of 134 m.Eq./L. on the
first day of the ACTH test. Girl no. 29, who showed no response to
ACTH and some impairment in response to "Metopiron", had a plasma
sodium level of 135 m.Eq./L. before and after ACTH.
Girl no, 5, who had an impaired response to ACTH and almost no
response to "Metopiron", showed a rise in plasma sodium from 140 to
154 m.Eq./L. during the ACTH test. A similar large rise from 138
to 150 m.Eq./L. was found in girl no. 20, who also had an impaired
response to ACTH and no response to "Metopiron".
The lowest plasma sodium values were found in the boys, and
they ore best shown in tabular form:-
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PLASM SODIUM VALUES. BOYS
atient Plasma Plasma ACTH "Metopiron" Thyroid




14 132 135 Subnormal No response Clinically
normal
16 132 - Subnormal No response Normal
26 134 137 Subnormal - Normal
29 135 138 Normal &oo& Hypo.
response
31 130 143 Normal No response Normal
35 135 135 Incomplete Impaired Normal
36 135 139 Normal Almost no Normal
response
With the exception of patient no. 31» the lowest resting
values for plasma sodium v/ere found in those boys with grossly-
impaired adrenocortical function, nos. 14, 16 and 26, and in
nos. 14 and 16, where the test was applied, there was no response
to "Metopiron".
The control of sodium and water metabolism in the presence of
hypopituitarism is not well understood. Some authors have
attributed the hyponatraemia to-water retention. MacLean and his
colleagues (1957) investigated the sodium balance in nine patients
who had hypophysectocy for breast cancer. In these patients,
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hyponatraeaia only occurred if the fluid intake was excessive in
the presence of a low sodium intake.
Lipsett, West, Maclean and Pearson (1957) also compared the
response to withdrawal of cortisone in hypophysectomised and in
adrenalectomised patients. The former tolerated withdrawal better
than the latter. It was considered that the existence of
aldosterone secretion or the presence of diabetes insipidus did
not account for this difference.
The increases in plasma sodium which occurred in girls nos. 5
and 20 after the administration of ACTH during the standard test
cannot be explained on the action of ACTH alone. This rise was not
seen in others with an impaired pituitary-adrenal axis (e.g. boys
nos. 14 and 16), but it was present in boy no. 31> who showed a
normal response to ACTH but no response to "Metopiron". Further
studies are needed to elucidate this finding.
ANAEMIA IN HYPOPITUITARISM
Pallor and anaemia have frequently been recorded as part of
the clinical description of hypopituitarism. Snapper, Green,
Hunter and Witts (1937) reported several instances of
hypopituitarism associated with achlorhydria, hyperchromia anaemia
and subacute combined degeneration. Escamilla and Liss^Kl942)
desoribed anaemia and achlorhydria in hypopituitarism in which
there was an average haemoglobin content of 6S^ and occasional
eosinophilia. In 1948, Daughaday and his colleagues indicated the
frequent finding in hypopituitarism of a striking pallor of the
face sometimes described as "waxy-white" or "alabaster". This
they attributed to loss of melanin from the skin and to the lack of
the normal capillary flush on exposed skin. The pallor which
Daughaday reported was more marked than would be expected from the
degree of anaemia usually found in his cases, which was of moderate
degree and which was characterised by normochromic cells.
Macrocytosis was a rare occurrence. Cook et al. (1951), described
unexplained refractory anaemia in two of seven hypopituitaxy
patients. The anaemia was again of moderate degree, normochromic,
and with mild leucopenia.
Hamilton Smith (i960) wrote of six cases of hypopituitarism
which had presented as "anaemia refractory to the usual
haematinics"• Treatment with iron, vitamin and folic acid for
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periods of one to ten years was unavailing until the evidence of
hypopituitarism was recognised. In Smith's series, the
erythrocytes were normocytic and normochromic, except in one
instance in which moderate anisocytosis and poikilocytosis and a
few macrocytes were found. In a second case there was a moderate
degree of hypochromia. Normoblastic erythropoiesis was seen on
examination of the bone marrow. The peripheral white count ranged
from 4,700 to 9»100 cells per cubic millimetre. One patient had a
relative lymphocytosis. Two others in whom the test was performed
showed free hydrochloric acid in the gastric contents.
Two girls in the present study (patients 9 and 15) were first
seen because of their small size. Clinical and biochemical
examination revealed the following abnormalities:- height
percentile ratings of below three, retarded bone age, marked
sensitivity to insulin, hypoglycemia (no. 15) and anaemia. Both
children showed a good response to ACTH during the standard test
but patient no. 15 showed some impairment of response to
"Metopiron". The "Metopiron" test on patient no. 9 could not be
interpreted as one of the urine specimens was accidentally lost.
There was no evidence of thyroid dysfunction nor was there any
impairment of fat absorption on a five-day balance (Baldwin et al.,
1962), In patient no, 9 attempts to treat the anaemia with iron
were unsuccessful.
The bone marrow findings, particularly in patient no. 15,
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were similar to those encountered in hypophysectomised rats,
namely, a hypooellular marrow and pancytopenia. Although the
anaemia of hypopituitarism is well-documented, the mechanism i3
obscure. A number of investigators (Garcia et al., 1951;
Contopoulo3, et al., 1953* 1954; and Van Dyke, et al., 1954s
1957)# have postulated the existence of a simple pituitary
erythropoietic factor with the bone-marrow as target-organ.
However, Gordon (1959)# in an extensive review of the
literature, provided abundant evidence against this theory.
The anaemia of hypopituitarism has been fully corrected in
rats by the combined use of cortisone, thyroid and testosterone
(Huguley, 19&0)• Similarly in human subjects, cortisone, thyroid
and growth hormone have been effective (Crafts and Meineke, 1959).
It is possible that the clinical findings in the children
under discussion could be entirely due to growth hormone
deficiency, but there is no satisfactory explanation for the
impaired response to "vetopiron" in patient no. 15. The action of
growth hormone on erythropoiesis is not known but it is partially
effective in restoring the anaemia of hypophysectcsnised rats
(Huguley, I960).
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SOME ORGANIC LESIONS ASSOCIATED 1'ITH
ENDOCRINE DYSFUNCTION
Two boys in this study were found to have suprasellar tumours.
Patient no. 2 had a cyst of Rathke's Pouch, and patient no. 30 had
radiological evidence of a craniopharyngioma. A third boy (no. 8)
was first admitted in infancy beoause of anaemia which was
diagnosed as erythrogenesis imperfecta. Both no. 2 and no. 8 were
found to be dwarfed on clinical examination, and both were well
below the third percentile for height. Patient no. 30 was not
dwarfed but his endocrine status was evaluated before operation
and he subsequently presented an interesting disturbance of growth.
Patient no. 2 and no. 8 showed clinical and biochemical
evidence of panhypopituitarism, whereas no. 30 showed no clinical
evidence of endocrine dysfunction apart from enlargement of the
penis and testes. Biochemical investigation in this child revealed
some degree of insulin sensitivity, using a very small dose of
insulin (0.05 units/kg. body weight), and raised level of urinary
17-ketosteroids. In addition, no. 8 was slate-grey in colour and
there was histological evidence of iron deposition in the skin.
This child had received multiple transfusions of packed red blood
cells from infancy and it seemed possible that his hypopituitaiy
state was due to deposition of iron in or around the hypophysis.
In the two years before operation patient no. 2 showed a
119.
Patient no. 2. Male, 12 years
STAHDING HEIGHT BEFORE AMD AFTER OPERATION
BOYS 9-18




gradual slowing down of growth (measured by standing height,
Pig, 8), and this remained at a constant value during treatment
with cortisone, ACTH, thyroid and pitressin immediately before,
during and after operation. When all therapy was stopped, the
boy grew one inch in height in the succeeding six months and it
seems probable that this retardation of growth was due to the
influence of adrenal steroids produced by exogenous ACTH, An
attempt was made to remove the iron deposits in patient no, 8 by
means of Desferrioxamine (Ciba Laboratories Ltd,), a reported
specific iron-chelating agent, but preliminary studies were not
encouraging (Dr. H.Sephton Smith),
Although the height measurements of patient no. 30 are not
available, this child grew very rapidly until at the age of nine
years he had a skeletal age of twelve years six months. There
were signs of puberty, except that tooth eruption was about
normal for chronological age and there was no axillary hair. The
urinary gonadotrophin activity was estimated at 3.2 units HMG
20A in twenty-four hours, but the significance of this was not
clear in view of the absence of normal values in children when
employing this method. According to Tanner (1962), accurate
assessment of the value of dental maturity is not possible because it
has not been sufficiently used as a measure of physiological maturity
at adolescence. However, it seems that development of the teeth,and
in particular, the rate of maturation, is more closely associated
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with skeletal age and secondary sex characters at adolescence, than
before, Demisch and V.artmann (1956) found a partial correlation
between skeletal age (Greulich-fyle) and the stage of third
mandibular molar development when chronological age was held
statistically constant. The absence of axillary hair in the
presence of a pubic hair rating of stage 4 (Tanner, 1955), is
unusual, but the time of appearance of axillary hair is variable.
The cause for this precocious puberty is not known but it may
be related to a disturbance of hypothalamic function. Precocious
puberty has been produced experimentally in some species by
anterior hypothalamic lesions. Methods of recording have shown
that there is activation of the anterior and lateral hypothalamus
during spontaneous ovulation in rodents with regular menstrual
cycles, or following vaginal stimulation in oestrous cats. The
activated areas are near the median forebrain bundle (Greer, I960).
Complex endocrine changes ranging from panhypopituitarism to
precocious puberty have also been described in lesions of the
hypothalamus with an anatomically intact pituitary gland
(Bauer, 1954).
In patient no. 2 there was evidence of restoration of
pituitary function following operation, but on testing the
adrenocortical response to ACTH it was found that the response was
less than when the child had been receiving thyroid. It is well
documented that surgical hypophysectomy in man is followed by a
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fall in indices of urinary gonadotrophin excretion, thyroid
function and 17-ketosteroid excretion (e.g. Luft and Olivecrona,
1953). At autopsy, atrophy of adrenals, gonads and thyroid
closely parallels that seen in hypophysectomised rats (Shimkin
et al,, 1952). As total hypophyseetomy in man is technically
difficult, residual hypophyseal cells not infrequently remain. In
partially hypophysectomised patients there is a restoration of
thyroid function after an initial fall (Elden and Kumraer, 1943)»
menstruation may return and pregnancy occur (Luft and Olivecrona,
1953). Similarly, in Sheehan's syndrome (Sheehan, 1939) where
residual hypophyseal cells remain, spontaneous recovery may occur.
This is accelerated if the patient subsequently becomes pregnant
(Sheehan and Murdoch, 1939).
CASE SUMMARIES
Patient No. 2:
This boy, aged twelve years ten months, was admitted with a
six-month history of temporal headaches which recurred every six
weeks and which lasted for two to ten days. The headaches were
very severe at times, he felt ill, became "greenish" in colour,
and he was very drowsy. The patient was in good general health
between headaches, and there was no vomiting unless he was forced
to eat. He attended an optician who found no visual disturbance
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to account for the headaches. The boy was slightly anaemic for
six months prior to admission.
X-ray examination of the paranasal sinuses at a local
hospital revealed an abnormally large pituitaiy fossa and an
extremely thin dorsum sella. This was confirmed by further skull
X-rays, Clinical examination of the central nervous system was
entirly normal, but accurate assessment of the visual fields
showed a definite loss of the upper left temporal region. He was
transferred to The Hospital for Sick Children for further
investigation and treatment.
On general examination the boy was found to be pale and small
for his age, with loss of hair on the skin. He had infantile
genitalia and the left testis was not palpable in the scrotum.
Examination of the central nervous system showed no abnormality
and the visual fields were full to confrontation, Perimetzy
confirmed the loss in the left temporal region which had been
reported previously.
Lumbar air-encephalography and "Myodil" ventriculography
(Br, R.D.Hoare) revealed the presence of a suprasellar
space-occupying lesion which projected into the basal cisterns and
caused a filling defect of the anterior part of the third ventricle.
There was no intracranial calcification. Films taken at another
hospital when the child was six years old showed a normal sella.
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Chemical and bacteriological examination of the cerebro-spinal
fluid, and the total and differential white blood count, were
normal. Haemoglobin was 11.4 g./lOO ml.
Biochemical investigation of the endocrine system before
operation showed a response to exogenous ACTH which was typical of
that seen in patients with hypopituitarism. The resting levels of
urinary 17-ketosteroids and total 17-bydroxycorticoids were about
one-tenth of normal. The ability to raise the 17-ketosteroids
after stimulation was also poor.
In addition, there was increased insulin sensitivity and a
high, flat glucose tolerance curve. Blood cholesterol was at the
upper level of normal, determinations of basal metabolic rate were
significantly low, but the serum protein-bound iodine valus of
more than 10 yg./lOO ml. was invalid because of previous "Myodil"
ventriculography.
The child was therefore treated with cortisone before,during
and after operation. A purplish tumour mass was found to occupy
most of the pituitary fossa and the sella turcica appeared
completely empty after removal. The lesion was diagnosed
histologically as a cyst of Rathke's Pouch by Dr. M.Bodian and by
Professor T.Crawford.
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The child*s post-operative condition was excellent but he
drank large quantities of fluids and he did not concentrate urine
■when the intake was restricted from 280 fluid ounces to 50 fluid
ounces each day. No pitressin was given. "^1 studies at
University College Hospital showed a low thyroid uptake. The
child was transferred to The Royal Marsden Hospital for
radiotherapy on a maintenance dose of 12.5 mg. cortisone acetate
twice daily, and Thyroid B.P., grains \ each day.
One month after operation and radiotherapy the patient was
readmitted for endocrine assessment. He had no complaints apart
from polyuria, and on examination he was pale, of small size, with
dry skin and fullness of the face. There were no signs of
pubescence and the left testis was not palpable in the scrotum.
Trial doses of ACTH were given and the urinary output of
17-ketosteroids and total 17-hydroxycorticoids was determined. On
stopping the ACTH it was found that the adrenal stimulating power
of the pituitary was inefficient but there was evidence of
restoration of pituitary function. The adrenocortical response to
the standard test with exogenous ACTH was normal. The dose of ACHi
was adjusted to 15 units daily on the basis of urinary steroid
output and the child was discharged on a fifteen-hundred Calorie
diet to prevent excessive weight gain, 15 units of ACTH gel daily
by intramuscular injection, Thyroid B.P. 1 grain each day and one
capsule of Pitressin snuff each day in divided doses.
126.
Seven months later all therapy was stopped and he was admitted
for endocrine assessment six months after that. On measurement at
the growth clinic (Dr. J.M.Tanner) it was found that the child had
grown one inch in height during the six months without therapy and
an ACTH test showed a good response to stimulation but
considerably less than that obtained when the child ?/as on
treatment three months after operation. The striking clinical and
biochemical features at this time were those of hypothyroidism.
Patient Ho. 50:
This boy, aged six years and ten months, was well until a few
months before admission when he complained of headaches and fits
which were diagnosed as Petit Mai. He was treated with "Tridione".
The fits continued and became more severe. They were of short
duration (five to ten seconds) and sometimes the child had five or
six fits a day, with intervals of half to three quarters of an
hour between each episode. Usually they ocourred first thing in
the morning.
During a fit, the boy would hold his head still, stare, then
drop his head. This was followed by normal behaviour. He was
incontinent of urine during a fit on three ocoasions only. There
was frequent vomiting in the two weeks before admission, which was
forceful and unrelated to food. The child felt sick for only a
few seconds before vomiting.
127,
General examination was normal apart from moderate
enlargement of the penis and testes, with some proliferation of
pubic hair. On examination of the central nervous system the
patient was found to have a head circumference of 57*5 cm.
(23 inches), bilateral constriction of the visual fields, and
marginal blurring of the discs associated with moderate
i^ypermetropia (Mr. J.H.Doggart) • X-ray films of the skull showed
an area of calcification 1 cm. in diameter in the region of the
right posterior clinoid process, and a lumbar air-encephalogram
(Dr. R.D.Hoare) confirmed the presence of a large suprasellar
tumour with hydrocephalus.
On biochemical investigation there was some degree of insulin
sensitivity after a small dose of insulin (0.05 units per kg. body
weight), and resting values of urinary 17-ketosteroids were raised.
There was a good response to exogenous ACTii and the serum
protein-bound iodine level was normal.
Treatment consisted of aspiration of the tumour (Mr. K.Till)
followed by radiotherapy.
The ohild was not brought to the Hospital until ten months
after operation. He was very well with no recurrence of fits.
Physical examination revealed a moderate degree of blindness in
the right eye and pallor of both optic discs. The penis and testes
had become more enlarged since operation. There was no axillary
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hair but pubic hair was present and urinary gonadotropins were
estimated at 3*5 units HMG 20A in twenty-four hours, although this
value could not be fully interpreted in the absence of normal
ranges in childhood by this method.
Ten months later the child was seen by Dr. J.M.Tanner when it
was found that his voice had broken and he had grown at "an
astonishing rate" since operation. The child's genital development
and growth of pubic hair were rated as stage 4 (Tanner, 1955)* The
testes were adult in size and consistency. He had erections but he
was not emotionally disturbed in the presence of girls. Examination
of the central nervous system showed no evidence of recurrence of
the tumour.
The child continued to grow very rapidly and when seen six
months later he appeared to be in a normal adolescent "growth-spurt'
but tooth eruption was about normal for chronological age. The
voice was deep and there was a light growth of hair on the upper
lip. There was no axillary hair but the pubic hair was between
stages 4 and 5» The penis was adult in size.
The following table lists estimations of skeletal age










* Estimated in the Department of Radiology.
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CHRONIC REGIONAL ILEITIS AND HYPOPITUITARISM
The relationship between malnutrition and hypopituitarism has
been well-described in experimental animals
(Bennett, Li and Evans, 1948; Li, Simpson and Evans, 1949J Samuels,
1950; D'Angelo, 1951) and in human subjects, chiefly the result of
war privations (McCullagh and Tupper, 1940; Sydenham, 1946; Thorn
et al, 1950). In 1959, Fletcher and Brown reported impaired
pituitary function in ten women who had severe loss of weight which
could only be ascribed to anorexia for which no organic cause
could be found*
Impaired pituitary function may also result from primary
disease of the alimentary tract. Mickerson (i960) described
defective end-organ response in a series of patients with
steatorrhoea. The author was unable to attribute his findings to
decreased caloric intake beoause he maintained that intestinal
absorption in steatorrhoea is considerably greater than that in
people who exist under famine conditions.
Several instances of dwarfism have been reported in children
with chronic regional Ileitis (Logan and Brown, 1938; Tanner, 1939;
Crohn and Yunich, 1941; Alvarez, 1945) and in each case, intestinal
symptoms comprised the chief complaint. Sobel, Silverman and
Lee (1962) reported two children with chronic regional ileitis who
presented with slow growth and who were at first considered to be
hypopituitazy dwarfs. These writers stressed the difficulty in
diagnosis which is exemplified by the foil owing case.
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An eight year old bey (patient No*20) ma first seen because
of alimentary symptoms, but radiological examination after brxiun
raeol showed no abnormality. In view of his anal also, retarded
skeletal age, anaemia and an impaired fat absorption of 91*8£, it
mis decided to treat him■initially on a gluten-free diet.
The ohild was seen nine months later when there was little
change in his physioal condition. A repeat fat balance showed
%;r absorption and there was ole rcut evidence of impaired
pituitary function on endocrine investigation. The nature of the
intestinal complaints remained obscure, and another barium meal
examination was carried out. Before hie next outpatient visit
the child was admitted with a diagnosis of appendix abscess which
was not upheld by the examining surgeon. He made the clinical
diagnosis of regional ileitis which was supported by radiological
examination, and by the findings at laparotomy.
The mechanism of the relat ionship between regional ileitis and
pituitary function is not known. Crohn and Yunich (1941) entioned
that where the disease begins before or at puberty, there is
considerable retardation of secondary sexual development. These
authors described one bey who responded to medical treatment and
who gained weight and who shewed norml secondary sexual maturation.
Sobel, Silverman, and Lee (1962) considered the hypopituitary
state to bo the result of ileitis, both patients described by
then improved dramatically after surgical treatment. In one child,
growth was again retarded when the disease recurred.
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Pituitary dysfunction in chronic regional ileitis may be the
result of diminished caloric intake or deficiency of a specific
dietary factor. Maddock and Heller (1947) provided evidence that
there might be a failure of the secretory mechanism of pituitary
hormones early in malnutrition. Samuels (1948) showed that in
rats, where gonadal atrophy occurred there was a negative nitrogen
balance. In further studies, he attempted to answer the question
whether lack of a specific amino acid was responsible, or whether there
was a general inability to utilise amino acids. He studied deficiency
of tryptophan, and found in the rat, that gonadal atrophy-
occurred in the absence of this amino acid even though total amino
acid and caloric intake were unchanged. In these animals both the
thyroid and pituitary were small at autopsy.
In this child there was impaired fat absorption before the
administration of a gluten-free diet, one must therefore consider
the possibility of deficiency of fat soluble vitamins in view of the
effect of certain vitamins on the ability of the end organs to
respond to gonadotrophs hormones (Mason, 1944? Herts and Tullner,
1949).
The maintenance of a negative nitrogen balance even though
small will result in impaired pituitary function. It is tempting
to attribute this child's endocrine dysfunction to malnutrition
but failure of growth was first noted on first appearance of
symptoms. One may question the reliability of the parents as
witnesses but in the absence of exact physical measurements this
argument must remain unsettled.
It seems possible that all patients with chronic regional
iletis have impaired pituitary function and that the partial
therapeutic success of ACTH or corticosteroids is primarily due to





METABOLIC STUDIES WITH HUMAN GROWTH HORMONE
It is a cardinal principle of medical treatment that
therapeutic trial of a specific agent is obligatory especially in
those cases where long-term administration is envisaged. This is
particularly applicable in hormone replacement therapy where the
substance to be given may have potent metabolic effects.
The studies to be described were undertaken,prior to
treatment, in four children in an attempt to evaluate the
efficacy of a Human Growth Hormone preparation. These children
were considered to have a probable deficiency of that hormone and
their mode of selection for metabolic investigation is discussed
elsewhere in this thesis.
Reifenstein, Albright and Wells (1945) presented a survey of
the methods then in use in The Metabolic Unit, The Massachusetts
General Hospital, in which they expressed the hope that some of
the methods might be adopted by others in order to establish
uniformity in the field. Most metabolic work is now based upon
the pioneer studies of this group.
Methods of Conducting Balances:
The present investigationsformed part of the work of the
Routine Laboratory, Department of Chemical Pathology, The Hospital
for Sick Children. In the absence of a special metabolic ward it
is the practice for metabolic balances to be carried out wherever
a child is situated. We have found this system admirable. The
balance is under the immediate supervision of the Ward-Sister or
Staff-Nurse, in close co-operation with the Diet Kitchen and the
Laboratory.
It is our practice to explain the nature and purpose of the
study to the parents and to the child where this is possible. It
is as important to gain the co-operation of the child in metabolic
work as it is in the physical examination. A written schedule
with a brief explanation of the studies to be undertaken is
distributed to the departments concerned before the balance is
begun.
Diet Shortly after admission, the child's dietary requirements
were assessed by the Dietitian in conjunction with the nursing
staff. During an interval of 5-7 days before the balance regime,
the child was allowed freedom of choice from those foods which
could be deep-frozen. Except in the case of patient number 24,
(C.L.), food was obtained in bulk at the start of the
investigation, distributed into meals and deep-frozen.
Food Balances were begun at 10 a.m. The child was given no
food except that supplied by the Diet Kitchen, although distilled
water was given in free amount. No tooth-paste was used
throughout the stuc^r period; teeth were cleaned with distilled
1J6
water only. A duplicate of all food and fluids given to the child
was sent to the laboratory daily, except where the Diet Kitchen
carried sufficient deep-frozen stocks, thereby limiting the
analysis to one day's meals. Milk samples and perishable
foodstuffs which could not be deep-frozen, and where composition
was subject to daily variation, were sent to the laboratory each
day.
At the end of each balance period the food and fluids were
pooled and homogenised in a plastic bucket with a Silverson
Laboratory Mixer-Emulsifier ("Silverson")j the homogenate was
made up to a suitable volume (usually 5-10 litres) with distilled
water. This was done by allowing the "Silverson" to run until a
homogenous fluid with no lumps was obtained. It was then stopped,
removed from the bucket, and the volume was made up to the nearest
mark. The "Silverson" was then replaced and run until the fluid
was thoroughly mixed. Milk was homogenised for only a few seconds
to prevent the formation of a thick froth.
Sampling of Homogenate Yihile the "Silverson" was running,
200 ml. of homogenate were transferred to a beaker and a further
100 ml. were placed in a polystyrene pot for storage at -20°C.
The pot was not filled more than two-thirds its volume because of
expansion on freezing.
Black-A3hing The 200 ml. of homogenate in the beaker were
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stirred continuously during the slow addition of 100 ml.
concentrated sulphuric acid (M. and B., R.R. Low in nitrogen).
V.here frothing occurred, the speed of stirring was increased.
Stirring was continued until room temperature was reached.
Material which had been properly ashed was jet black, where it was
brown more sulphuric acid was added. The black liquid was mads up
to 500 ml. and mixed. This was known as the "black-ashed material"
and an aliquot of approximately 100 ml. was stored in a
polystyrene pot at room temperature.
Rejects Rejects were sent to the laboratoxy from the Diet
Kitchen at the end of each period. They were treated exactly as
diets.
Vomit Wherever possible, vomit was sent for analysis and the
specimens were included in the rejects.
Urine Urine was collected over 24-hour periods from 10 a.m.
At this time on the first day of the balance, the patient emptied
his bladder and this specimen was discarded. All urine passed up
to and including the specimen at 10 a.m. the next day was saved in
polythene bottles containing 5 ®1« of glacial acetic acid. These
were labelled with the child's name, the dates of both days
covered by the collection, and the exact time of commencement.
If any specimen was accidentally lost, details of the time passed
and an estimate of the volume (where possible) were sent to the
laboratoxy.
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Stool The collection of urine and faeces in children, Kith
particular reference to infants and incontinent patients, has
been described by Baldwin et al. (1962). The method of stool
collection in this study was based on that reference. Each stool
was colleoted separately in polythene sheeting and the complete
specimen was placed in a waxed paper carton which was labelled
with the child's name, the date and the time at which the stool
was passed. Record sheets were issued to the ward for this
purpose. For timed faecal collections it was necessary to give a
marker. Charcoal was unsuitable, therefore for those children
over one year of age, carmine powder grains 5 and Edicol Supra
Blue E.G. (Imperial Chemical Industries Ltd.) 1 mg./kg. body
weight were given alternately. Faeoal collections were begun at
the first appearance of the dye. Stools were saved until the
second marker appeared, and the stools containing the second
marker were sent to the laboratory. The marked stool was not
included in the analysis unless the balance was continuing, and
then it became the first speoimen of the next period.
Before homogenising, all specimens of faeces were checked
from laboratory records against those of the ward. All the stools
for each balance period were bulked and homogenised; the known
volume was such that a homogenate of manageable consistency was
obtained. 200 ml. of this was black-ashed and stored using the
method which was applied to the diets. A new model of the
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Silverson homogeniser is now available which is particularly
suited for faeces. It has a totally enclosed rotor arm thereby
minimising aerosol formation.
METHODS OF ANALYSIS
Procedure for Digesting Calcium and Phosphorus
Reagents:
1. Concentrated sulphuric acid S.G, 1.84 (Analytical
Reagent (A.R,)).
2. Hydrogen peroxide 100 vols. (A.R.). Stored at 4°C.
3. Sodium acetate (A.R.) 20$ w/v anhydrous salt in aqueous
solution.
4. Bromocresol green (B.D.H.).
5. Ammonia. 0.880 (A.R.).
6. Glacial acetic acid (A.R,), 33$ v/v in aqueous solution.
(1-5 ml.)* of black-ashed material or urine was
pipetted in duplicate into micro-Kjeldahl flasks calibrated at
20 ml. 1 ml. concentrated sulphuric acid and a 2 mm. diameter
glass bead were added. The flask was heated on a digestion rack
until the sulphuric acid was anhydrous and extreme care was taken
to prevent fluid loss through bumping, there large amounts of fat
were present the food blackened and appeared to absorb sulphuric
* Stool + urine: 1 ml. Stool: 2 ml. Urine: 5 ml.
Black ashed diet, rejects, milk: 5 ml.
acid. When this happened, a further 1 ml. of acid was added.
When the acid was anhydrous and refluxing gently, the flask
was removed from the flame and a few drops of hydrogen peroxide
were added directly to the hot acid, with the mouth of the tube
pointing away from the operator. The flask was replaced on the
digestion rack and boiled until the water was driven off. The
addition of peroxide was repeated until the fluid remained clear
after fifteen minutes* boiling. The tubes plus contents were
allowed to cool, 5 ml. of distilled water were added, the contents
were mixed by swirling and allowed to cool again. 1 ml. of 20j&
sodium acetate solution and 4 drops of bromocresol green were
added. 0.880 ammonia was then added until the indicator turned
blue-green (pH 4.5 - 5.0) when compared with a standard. Where
necessary the pH was adjusted with 33% acetic acid and the contents
were made up to the 20 ml. calibration and mixed.
This was known as the "blue-green liquid" and was used for
calcium and phosphorus estimations.
Procedure for Estimating Calcium
Reagents:
1, Standard Calcium Solution 10 mg./lOO ml. 250 mg. of calcium
carbonate (A.R.) were dissolved in 6 ml. N/l hydrochloric acid
added dropwise. The mixture was gently heated on a boiling-
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water bath until all the hydrochloric acid had vaporised.
(The vapour was tested with blue litmus paper). The solution
was cooled anddiluted to one litre.
2. Ammonium oxalate saturated solution. This contained
approximately 45 g#/L. ammonium oxalate (A.R.) and was
filtered before use.
3. Dilute ammonia. 20 ml. 0.880 ammonia (A.R.) diluted to
one litre.
4. Sulphuric acid (A.R.), approximately N/l 2.8 ml. concentrated
acid/100 ml,
5. Stock potassium permanganate solution N/lO 3.D.H. Standard.
6. Working potassium permanganate N/50. This was made by
diluting the stock solution 1:5. It could be used for one
week if stored in a dark covered bottle. The normality was
not adjusted.
Method: 10 ml. of the "blue-green liquid" were transferred to a
50 ml. conical centrifuge tube. 1 ml. of saturated ammonium
oxalate was added to each tube and to 5 ®1» of the standard calcium
solution in a similar tube. A "blank" was also set up which
consisted of 5 ml. of water and 1 ml. of ammonium oxalate. The
tubes were shaken to mix and left overnight at room temperature to
precipitate the calcium oxalate.
The tubes were spun at 2,500 r.p.m. for 30 minutes. The
supernatant was removed by gentle suction with a hooked Pasteur
pipette, and the precipitate was washed three times with 5 ml» of
dilute ammonia. The latter was added gently from a wash bottle
with a fine jet. The sides of the tube were washed down without
disturbing the precipitate. The tubes were centrifuged for
10 minutes at 2,500 r.p.m. after each wash and the supernatants
were removed as before.
Finally, the caloium oxalate was dissolved in 2 ml. of N/1
sulphuric aoid at 60-70°C and was titrated with N/50 potassium
permanganate while still hot. A 5 nl. burette graduated in





Titration of standard x X Volume of "blue-green
liquid" used
x Total volume black ashed material
Volume of black ashed material used
Volume of homofienate made
_ mg. Calcium in
Volume of homogenate used ~~ total original sample.
Caloium Determination by Flame Photometer
Instrument: "Eppendorf" flame photometer
2
Fuel/gas systems: Calcium, air, 0.5 mg./cm. /acetylene,
0.42 L./minute.
2
Sodium, air/propane air 0.5 mg./cm. /propane
mm/E?S.
Filters: Calcium band 620 mjj.
Sodium line 589 mjj.
Solutions:
1. Calcium stock standard (20 m.Eq. ealcium/L.)
1.000 g, dry calcium carbonate (A.R.) was dissolved in
25 ml. N/l hydrochloric acid and made up to one litre with
de-ionised water.
2. Working calcium standard (0.2 m.Eq. calcium/L.). 1 ml. of
stock solution was diluted to 100 ml. with de-ionised water.
Ten scale divisions on the photometer were equivalent to
0.2 m.Eq. calcium/L.
3. 0.1 N hydrochloric acid.
4-. Sodium stock standard (100 mJSq. sodium/L.).
5.85 B» dry sodium chloride (A.R.) was dissolved in
de-ionised water and made up to one litre. Dilutions of this
standard were made to cover a range of up to 50 m.Eq. sodium/L.
A calibration curve was constructed from which the sodium
content of the samples could be determined.
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Experimental: The instrument was shown to behave linearly to
calcium concentrations up to 0.5 m.Eq. calcium/L. At the
concentrations of calcium present in the diluted samples (below
0.2 m.Eq./L.) it was found that sodium was the only interfering
substance. For each milliequivalent of sodium present in the
diluted sample it was necessary to deduct 0.002 m.Eq. calcium from
the apparent calcium content.
Preparation of samples: 10 ml. aliquots of homogenised food or
faeces were transferred to 100 ml. silica beakers. Urine was
thoroughly mixed and 20 ml. samples were pipetted into silica
beakers.
Ashing: Samples were slowly dried on a sand bath before ashing at
420°C in a muffle-furnace overnight.
The residue was heated with about 10 ml. of N/10 hydrochloric
acid for ten minutes on a sand bath. When cold, the extract was
filtered through an acid-washed Whatman No. 42 filter-paper into a
25 ml. volumetric flask for food extracts or a 50 ml. volumetric
flask for faecal extracts.
The paper and funnel were thoroughly washed with portions of
N/10 hydrochloric acid and the extract was made up to the required
volume.
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Estimation: Samples were further diluted so that the estimated
concentration of calcium in the sample was below 0.2 m.Eq,/L. The
calcium emission from the samples was compared with that from a
standard solution containing 0.2 m.Eq. caleium/L.
The sodium content of the diluted samples was estimated and
the apparent calcium content was corrected for sodium enhancement.
Procedure for Estimating Phosphorus
Reagents:
1. Standard Phosphorus Solution - 25 rag./lOO ml. 1.0975 g.
potassium dehydrogen phosphate (A.R.) was dissolved in ion-free
water and diluted to one litre, A few drops of chloroform as
preservative were added. The solution was stored at 4°C.
2. Briggs Molybdate Solution. 25 g. of crushed ammonium molybdate
(A.R.) were dissolved in about 300 ml. of water. 75 ®1» of
concentrated sulphuric acid (A.R.) were added to 125 ml. of
\vater and when cool this was mixed with the ammonium molybdate
solution and diluted to 500 ml.
3. Hydroquinone 1$ w/v solution. This was made freshly for each
set of determinations.
A. Sodium sulphite (A.R.) 42/ w/v. 42 g. NagSo^, 7 HgO were
dissolved in warm water and diluted to 100 ml. when cool. Care
was taken not to overheat.
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Method; Sufficient 50 ml. volumetric flasks to allow two for each
test, one for a standard and one for a blank, were taken. The
following solutions were added to each flask and the contents were
mixed after each addition:-
40 ml. water.
2.5 ml. Briggs Molybdate Solution.
0.5 ml. Pfydroquinone.
0.5 ml. Sodium sulphite.
1 ml. of standard phosphorus solution was added to one flask
and an aliquot* of blue-green liquid" to the others so that a
colour approximately that of the standard was obtained. The
solutions were made up to the calibration, mixed by inversion and
allowed to stand for 60 minutes at room temperature; they were
then read on an EEL colorimeter in 1 cm. cells using a 607 filter.
Calculation:
Reading of test Q 2e- 20
Reading of standard x * x Volume of "blue-green
liquid used
x Total volume black-ashed material
Volume of black-ashed material used
Volume of homogenate made
_ mg. Phosphorus in
Volume of homogenate ashed total original sample.
* Stool, urine: 2 ml.
Milk, diet, rejects: 4 ml.
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Alternative Procedure for Estimating Phosphorus
The method of Gomorri (1942) was followed but N/lO HC1 was
used instead of 10$ w/v trichloracetic acid.
Reagents:
1. N/10 Hydrochloric acid (A.R.),
2. Ammonium molybdate solution. 7*5 g* ammonium molybdate (A.R.)
was dissolved in about 200 ml. of water. 100 ml. 10 N
sulphuric acid was added and the solution made up to 400 ml
with water.
3. MMetol" (p-dimethylaminophenol sulphate). 1 g. was dissolved
in 100 ml. 3$ w/v solution of sodium bisulphite (A.R.).
4. Standard phosphate solution (5 mg. phosphorus/100 ml.).
0.2197 g» potassium dihydrogen phosphate (A.R.) (KHg P0^) was
dissolved in water and made up to one litre. A few drops of
chloroform were added as preservative.
Method: Aliquots of the hydrochloric acid extracts of food and
faeces were made up to a volume of 5 ®1« with N/10 hydrochloric
acid. Urine was diluted 1:25 and 1 ml. of the diluted urine was
made up to 5 ml. with N/l0 hydrochloric acid.
Ammonium molybdate (l ml.) was added to each tube and after
thorough mixing,"Metol" (l ml.) was added at half-minute intervals.
A blank and standard (which contained 0.5 ml. standard phosphate
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solution) were included in each set of determinations. The
solutions were allowed to stand at room temperature for thirty
minutes. The colour was read at 607 in an EEL colorimeters
using 1 cm. cells.
Calculation;
Reagents:
1. Boric acid + indicators.
Solution Aj 100 mg. phenolphthalein to 100 ml. with 36fo v/v
Volume of aoid extract
made
Volume of acid extract
used
Volume of homogenate made
Volume of homogenate ashed
= mg. Phosphorus/specimen.
Procedure for Estimating Nitrogen
ethanol.




200 ml. Industrial methylated spirit
to dissolve and
700 ml. distilled water
diluted to one
35 ml. solution A
litre with water.
10 ml. solution B /
2. Sulphuric acid N/70. This was prepared from B.D.H. Standard
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N/7 acid or by dilution of concentrated sulphuric acid with
standardisation against boiling sodium carbonate.
3. Sodium hydroxide (A.R.) 40$. This was stored in an air-tight
polythene bottle. If a high blank was obtained, ammonia-free
air was drawn through the solution for several hours.
4. Selenium catalyst. Using a large "Amal" burner, 100 g.
selenium metal (A.R.) was boiled with one litre concentrated
sulphuric acid S.G. 1.84- (M. & B., low in nitrogen) until
colourless. The solution tended to turn yellow on standing and
where a precipitate formed the reagent was discarded.
Method: 1 ml. or a suitable sample* of black-ashed material or
0.20 ml, of urine was delivered in duplicate from an Ostwald
pipette into a micro-Kjeldahl flask which contained a glass bead
to prevent bumping. 1 ml. of selenium catalyst was added and the
flask was heated on a micro-digestion rack so that the contents
boiled vigorously without "bumping". Heating was continued until
all the water was boiled off and the solution cleared. The
solution was boiled for a further thirty minutes, cooled and
steam-distilled in a Markham apparatus.
Calculation: 1 ml. N/70 acid S 0.2 mg. nitrogen.
* The volume taken was such that a titration of between
2 and 10 ml. was obtained.
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Procedure for Estimating Sodium and Potassium
These were estimated, in duplicate, on the unashed homogenate
and on the urine directly.
Method: 25 ml. of homogenate was gently heated with 3 ml*
concentrated nitric acid in a 50 ml. conical flask. This was done
on a sand bath. The digest was brought to boiling point when a
definite coagulase appeared (yellow solid in a yellow liquid). The
flasks were cooled and the liquid was filtered through a fluted
Whatman No. 42 filter paper into a 100 ml. volumetric flask. The
conical flask and the precipitate in the filter-paper were washed
three times with distilled water. The yellow solution was made up
to 100 ml. with distilled water and then further diluted 1:25 to
give a reading measurable on the flame photometer.
Urine was diluted 1:100 without digestion. The flame
photometer was calibrated from 0-150 m.Eq./L. and these dilutions
were usually suitable, although sometimes it was necessary to use
others.
All glass-ware was well rinsed with ion-free water before use
and checked on the flame photometer. A deflection of not more than
two divisions was obtained with the sodium filter and the
sensitivity at full-scale.
Calibration of the Flame Photometer
Reagents:
1. Stock Solution. 150 m.Eq./L. Sodium and Potassium. 8.775 g»
sodium chloride (A.R.) and 11.2 g. potassium chloride (A.R.)
were dissolved in water and diluted to one litre. The salts
had previously been dried at 110°C overnight and allowed to
cool in a dessicator.
2. Working Solution. The Stock solution was diluted 1:10 and
1, 2, 3, 4, 6, 8 and 10 ml. of this were diluted to 100 ml.
(= 15» 30# 45» 60, 90, 120 and 150 m.Eq./L.f respectively).
The photometer was set on 100 with the strongest working
solution and all the others were read at this setting. The zero
and full-scale deflections were checked between each reading. A
graph of concentration against reading was plotted and the
concentration of the test was read from this. This was multiplied
by 100 for comparison with the stock standard.
The graph was drawn on two separate occasions to confirm the
stability of the flame photometer.
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CLINICAL TRIAL
Balance studies were carried out on four boys (patients 12,
24, 31 and 33)• In the first three children no abnormality was
found on physical examination or laboratory investigation, apart
from small size, retarded bone age, and marked sensitivity to
insulin. In addition to these anomalies, patient number 33 was
shown to have impaired adrenal function. When these metabolic
studies were carried out it was considered that patients 12, 24
and 31 exhibited possible growth hormone deficiency. However, in
the light of further investigations on normal and dwarfed
children, these patients also show some degree of impaired
function of the pituitary-adrenal axis.
On completion of two five-day control periods, 10 mg. Human
Growth Hormone (M.R.C. Raben preparation) were given by deep
intramuscular infection at 10 a.m. on the first day of the third
period. The balance was continued for two five-day periods after
injection in patients 12 and 24. Unfortunately, patient 33 was
not given a marker on the fifth day after growth hormone, and
this period was extended to seven days. In patient 31# the
urines on the fourth and fifth days after injection were pooled
on the ward, therefore half the 48-hour value was taken for each
day. The results of the studies in patients 12, 24 and 33
suggested that an additional five-day period after growth hormone
might yield more information, and this was done in patient 31.
Nitrogen, phosphorus (as phosphate), calcium, 3odium, and
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potassium were determined on dietary intake, faeces and urine on
each child. Plasma electrolytes, blood urea, alkaline
phosphatase, calcium, phosphorus and creatinine were also
determined where practicable. A complete set of plasma values was
not obtained in every instance because of the difficulty in
collecting sufficient blood for determination by micro-method,
particularly in patient 33 who was very small and who did not
bleed readily from a finger prick.
The results are presented in diagrammatic form according to
the method of Bassett (Bassett, personal communication quoted by
Reifenstein, Albright and Veils, 1945)• The scale for intake and
balance in g./24 hours, mg,/24 hours, or m.Eq./24 hours is given
as the ordinate. The time-scale, in days, is given as the
abscissa. The broken horizontal line at zero of the ordinate is
the base-line to which intake and balance refer.
The intake is plotted as an area from the base-line towards
the bottom of the diagram. The excretion is plotted from the
bottom of the intake to the top of the diagram. The areas in
black represent the faecal excretion during the five-day periods.
The daily urinary excretions are plotted from the top of the
faecal excretion to the top of the diagram. If the excretion does
not reach the base-line, a white area is left between the
excretion line and the base-linej this represents a positive
balance. If the excretion reaches the base-line, the balance is
on equilibrium. If it exceeds the base-line, then this
represents a negative balance. Reifenstein, Albright and Welle
(1945) tried many different kinds of chart but Bassett's method
allows one to focus on the balance, which is the most important
aspect of the study. This is not so with other methods of
presentation, where intake and excretion are plotted from the
same base-line.
Interpretation:
Since dietary intakes are accurate within lOfo in most
instances (Reifenstein, Albright and Wells, 1945)» any
significant fluctuation in the overall balance must be more than
&#.
In the following charts (Figs. 9 to 32, inclusive) and
tables (Tables 27 to 46, inclusive) the results of the balances
and analyses on blood and plasma are presented.
PATISCT HQ. 12 (M.F.. MALE)
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PATIENT NO, 12 (M.F., MALE)
Period: 1 2 3 4
Dates: 10-15.2.61 15-20.2.61 20-25.2.61 25.2.61-2.3.61
Diet 56.3 55.1 56.1 55.9
Rejects -M JL& Jag ^1
Intake 52.5 51.3 51.9 52.8
Urine 39.0 41.1 39.3 42.6
Faeces 4.1 3.6 44
Output 43.1 44.7 43.0 kb*o
Balance/5 days +9.4 +6,6 +8.9 +6,2
Balanoe/l day +1.9 +1.3 +1.8 +1.2
Daily urinary output:























PATIENT NO. 2U (C.L.. MALE)
NITROGEN BALANCE
C. L. NITROGEN BALANCE
Growth hormone given
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PATIENT NO. 24 (C.L.. MALE)
Period: 12 3 4
Dates: 26-31.3.60 31.3.60-5A.60 5-10.4.60 10-15.4.60




Intake 35.5 34.0 34.2
Urine 25.5 23.9 22.6 28.3
Faeces Jhi 3A 3.4 4.1
Output 30.6 27.5 26T0 32.4
Balance/5 days +6 +8 +8 +1.8
Balance/1 day +1.2 +1.6 +1.6 +0.4
Daily urinary output:





































PATIENT NO. 51 (p.R.. MALE)
Period: 1 2 3 4 5
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PATIENT NO. 35 (C.R.. MALE)
Period? 1 2 3 4
Dates; 16-21.6.61 21-26.6.61 26-3.7.61 3-8.7.61
Diet 24.1 23.7 32.3 25.4
Reject JLI 3.4 JL&£ -LA
Intake 20.9 20.3 29.1 24.0
Urine 20.0 19.1 22.0 20.4
Faeces JL*1 2.1 1.6
Output 21.7 21.2 24.5 22 .0
Balance/5 days -0.8 -0.9 +5.6(7d^s) +2.0
Balance/1 day „ —0.2 -0.2 +0.8 +0.4
Daily urinary output:


































PATIENT NO. 12 (M.F .. MALE)
Period: 1 2 3 1




































































PATIENT NO. 24 (C.L., MALE)
Period: 1 2 3 4
Dates: 26-31.3.60 31-5.4.60 5-10.4.60 10-15.4,
Diet 3240 3150 3000 2520
Reject nil nil nil nil
Intake 3240 3150 3000 2520
Urine 276 223 212 136
Faeces 2420 2670 lggQ 1600
Output 2893 2162 173
Balance/5 days +544 +252 +838 +734
Balance/l day +109 +50 +168 +157
Daily urinary output:
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CALCIUM (mR.)
PATIENT HO. 31 (P.R.. MALE)
Period: 1 2 3 4 5













































































































PATIERT NO. 35 (C.R.. MALE)
Period: 1 2 3 4
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PATIENT NO. 12 0.1.F.. MALB)
Period: 12 3 4-
Dates: 10-15.2.61 15-20.2.61 20-25.2.61 25-2.3.51
Diet 6513.2 6220.6 6188.3 6458.7
Reject 506.8 320.7 456.1 252.8
Intake 6006.4 6541[3 5732*2 6711.5
Urine 2602.5 2824.9 2681.7 2840.1
Faeces 2500.0 2000.0 2166,7 2192.0
Output 5102.5 4824.9 4848.4 5032.1
Balance/5 days +903.9 +1716.4 +883.8 +1679.4
Balance/1 day +180.8 +343.3 +176.8 +335.8
Daily urinary output:




























PATIENT HQ, 24 (C.L.. MALE)
Period: 12 3 4
Dates: 26-31.3.60 31-5.4.60 5-10.4.60 10-15.4.60
Diet 4600 4000 4300 4250
Reject nil 18 nil 59
Intake 4^00 39^2 4300 U91
Urine 2150 1828 1324 1822
Faeces 2030 1970 1350
/«
Output 4180 J798 2674 3972
Balance/5 days +420 +184 +1626 +219
Balanoe/l day +84 +37 +325 +44
Daily urinary output:






















P\TIENT NO. 31 (D.B„ MALE)
PHOSPHORUS BALANCE
PHOSPHORUS BALANCE






PATIENT NO. 31 fD.R.. MALE)
Period: 1 2 3 4 5























































































































+415.1 (7 <^s) +223.1
+59.3 +44.8
Daily urinary output?
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PATIENT NO. 12 (M.F.. MALE)
Period: 12 3 4
Dates: 10-15.2.61 15-20.2.61 20-25.2.61 25-2.3.61
Diet 287.3 283.8 290.5 287.1
Reject 16.8 14.2 16.5 7.1
Intake 270.5 2&9T& 274.0 280.0
Urine 198.2 226.1 244.5 238.2
Faeces 1.2 0.9 1.3 1.8
Output 199.4 227.0 24578 2^0
Balance/5 days +71.1 +42.6 +28.2 +40.0
Balance/1 day +14.2 +8.5 +5.6 +8.0
Daily urinary output:






















PATIENT HQ. 24 (C.L.. MALE)
SODIUM BALANCE
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PATIENT NO, 24 (C.L.. MALE)
Period? 1 2 3
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PATIENT HO. 51 (D.R.. MALE)
Period: 1 2 3 4 5
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PATIENT NO. 53 (C.R.. MALE)
Period: 1 2 3 4
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PATD1HT NO. 12 (M.F., MALE)
Period: 12 3 4
Dates: 10-15.2.61 15-20.2.61 20-25.2.61 25-2.3.61









Urine 240.6 249.5 249.5 265.9
Faeces 24.0 17.5 18.0 22.5
Output 264.6 2&770 2*57.5 288.4
Balance/5 days +29.2 +10.5 +28.9 +25.4
Balance/1 day +5.8 +2.1 +5.8 +5.1
Daily urinary output:





















PATIENT NO. 2L (C.L, , MALE)m-. vr. —»#r. ret *•, • i>*; ■».-. *,■■>-■,..! rx. «-.-*» *- te- .Car
POTASSIUM BALANCE
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C. L. POTASSIUM BALANCE
Growth hormone
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PATIENT NO. 24 (C.L.. Mi'LB)
Period: 12 3 4
Dates: 26-31.3.60 31-5.4.60 5-10.4.60 10-15.4.60
Diet 252.0 283.0 252 234.00
Reject 1.3 1.5 nil 0.75
Intake 250.7 281.5 252 233.20
Urine 188 184.4 156.5 190
Faeoes 42 40.0 64.0 48
Output 230 224.4 220.5 238
Balance/5 days +20 +57.1 +31.5 -5
Balance/1 day +4 +11.4 +6.3 -1
Daily urinary output:
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PATIENT NO. 51 (D.R.. MALE)
Period: 1 2 3 4 5
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PATIENT NO. 33 (C.R,,. MALE)
Period: 1 2 3 4















































































Reports of the metabolic effects of various preparations of
Human Growth Hormone have been adequately reviewed by Raben (1962)
and there is abundant evidence of its potent anabolic actions,
which have also been studied in hypoprituitary dwarfs (Hutchings,
Esoamilla, Dearner and Li, 1959; Shepard, Nielsen, Johnson and
Bernstein, I960; Shepard, Waxman, Bernstein and Ferrier, i960).
The work of Shepard and his colleagues is open to criticism
in that the first set of balance studies was done on a "free" diet
without the use of stool-markers, and in the second set there was
no constant dietary intake, and stools were not analysed. When
one is seeking small but significant changes in balance one must
analyse dietary intake, faeces, and urine. In view of this, a
critical assessment must also be made of Ducharme and Grumbach's
report (1961) of the ineffectiveness of Human Growth Hormone in
"normal" premature infants, as the dietary intake was not
analysed in this study.
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Apart from differences which may exist in the properties and
potency of Human Growth Hormone preparations, there is no
agreement as to the mode of selection of hypopituitary dwarfs for
therapy, and little attempt has been made to apply standardised
tests of endocrine function. Shepard and his colleagues (i960)
defined their patient as a "constitutional or primordial dwarf"
on the criteria described by MoCune (194-3), but this definition
was incomplete and their attempts to evaluate pituitary function
were poor. Again, Lipsett, Bergenstal and Dhyse (1961) described
metabolic studies with Human Growth Hormone in "primordial"
dwarfs, and their indices of thyroid and adrenal function were
based upon serum levels of protein-bound iodine and Cortisol.
The value of both these tests has been discussed in the first
section of this thesis. One must, therefore, exercise caution in
the interpretation of balance studies with Human Growth Hormone
which are described in the literature in so-called "hypopituitary"
dwarfs•
Nitrogen Metabolism.
There was no significant change in the faecal excretion of
nitrogen in any patient after the administration of growth
hormone in the present series. A fall in urinary nitrogen
occurred in patient no. 12 which was most pronounced in the
first twenty-four hours after injection, and which lasted for
three days. Apart from a marked reduction in urinary nitrogen
during the second twenty-four hours after hormone, there was no
sustained effect in no. 24. Patient no. 31 showed no alteration
of urinaiy nitrogen, but no. 33 revealed a definite trend
towards nitrogen retention in the second half of the third
balance period, and in the first four days of the last period.
There was a sharp fall in blood urea in patients 12 and 24
within twenty-four hours of injection. This was not marked in
no. 31» and in no. 33 the change was most pronounced in the
second twenty-four hours after growth hormone. This reduction in
blood urea is the earliest effect of growth hormone on human
nitrogen metabolism which has so far been described. This is
most probably a reflection of the anabolic action of the hormone
and it has been observed six to twenty-four hours after a single
injection (Pearson, Lipsett, Greenberg and Boy, 1957;
Haben, 1959).
In Beck's series (i960), which included one lypopituitary
dwarf, the fall in blood urea occurred on the second, third and
fourth day after injection and persisted for two to three days.
Again, in Beck's patients, decreased urinaiy excretion of
nitrogen was usually demonstrable on the second day after
injection, and was maximal on the third to the sixth day.
Raben (1962) has already stated that the distribution of
this nitrogen retention is not known, but the failure of growth
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which occurs in hypophysectomised animals, and the increased rate
of somatic growth which follows growth hormone therapy in these
animals, are indications of the endocrine control of protein
synthesis. Szego and White (1942) showed that the metabolic
effects of growth hormone are seen in fasting as well as
non-fasting animals, and they showed that alteration in protein
metabolism could be achieved with growth hormone, even where gain
in body weight did not occur. They postulated that the
primary action of growth hormone was on the liver, and this is
suggested by an "intense mobilisation" of lipid to that organ.They
claimed that growth hormone could thus exert a sparing action on
protein catabolism, thereby making available a greater portion of
amino acid nitrogen for protein synthesis. They also suggested
that this well-documented lipid mobilising effect (Levin and
Farber, 1952; Greenbaum and McLean, 1953, Raben and Hollenberg,
I960), would also provide energy for protein synthesis. Further
work by Kostyo and Knobil (1959) has shown that increased
cellular penetration of amino acids caused by growth hormone
favours enhanced protein synthesis. In addition, there is
evidence by Korner (1961) that growth hormone increases the
synthesis of protein by isolated liver ribosomes from the
hypophysectomised rat.
Calcium Metabolism,
A significant reduction in the faecal excretion of calcium
was seen in patients 12 and 24. This occurred in the five-day
period following injection and was continued throughout the
fourth period in patient no. 24, in spite of a reduced intake.
This increased intestinal absorption of calcium has bean
described by others (Panel appointed by the Clinical
Endocrinology Committee of the Medical Research Council, 19595
Fraser and Harrison, 1960} Hanna, Harrison, Maclntyre and
Praser, I960). Patients 31 and 33 showed no change in the
faecal output of calcium.
There was no change in urinary calcium in patient no. 12,
but no. 24 had a reduced excretion from the fourth to the eighth
day after injection. No. 31 showed a gradual reduction in
urinary calcium which was most obvious in the second five-day
period after hormone administration. A similar trend was
illustrated by patient no. 33 from the fourth to the seventh day
after injection} thus no patient showed hypercalciuria which was
the most striking metabolic feature described by the Medical
Research Council Panel (i960). After a 10 mg. dose of Human
Growth Hormone given intramuscularly, Fraser and Harrison (i960)
found a moderate increase in urinary calcium which lasted about
seven days, and after a dose of 30 an equivalent increase in
urinary calcium occurred which lasted for fourteen to twenty-one
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days. Little difference was found In urinary nitrogen between
the two doses, and Fraser and Harrison (i960) believed large
doses of Human Growth Hormone stimulated parathyroid activity,
and they claimed that good support for this belief was found in
the literature. However, Copp (1955) showed that in rats which
were treated with growth hormone, decreased phosphate intake
caused a marked mobilisation of skeletal minerals so that levels of
urinary calcium rose, and considerable demineralisation of the
skeleton occurred. If the phosphate intake was normal, then
decalcification did not occur, and Copp concluded that the primary
effect of growth hormone on bone was on the deposition of protein
matrix. Pearson, Soroff, Prudden and Schwartz (i960) reported that
after the administration of Human Growth Hormone in adults, the net
oalcium balance depended on the intake. If the intake exceeded a
certain "critical level", retention occurred} if the intake fell
below that level, growth hormone increased the loss.
The effects of growth hormone on calcium metabolism remain
controversial, but two points are worthy of consideration. First,
the effect of growth hormone on the hypopituitaxy child is
probably different from the effect on the adult, and vastly
different from the effect on the hypophysectomisad adult with
malignant disease. Second, the form of calcium in the dietaxy
intake may be an important factor. The Hammersmith Group (Hanna,
Haxvison, Maclntyre and Fraser, I960), employ a low calcium diet
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with calcium supplements, whereas in The Hospital for Sick Children
balance studies are carried out on the child's usual dietary
intake.
In the present series, levels of plasma calcium in patient
no. 12 showed no constant features. In no. 24, there was a
gradual rise from the fourth to the eleventh day after injection.Beck
et al(l96o) reported no significant change in serum calcium during
growth hormone administration.
Phosphorus Metabolism.
There was a significant reduction in the faecal excretion of
phosphate in patient no. 24 in the five-day period which followed
the administration of growth hormone. This effect was not seen in
the other children. Again, in no. 24, there was a marked
reduction in urinary phosphate in the same period, which was
followed by a tendency to negative balance in the succeeding five
days. Patients 12 and 33 showed no change in urinary excretion,
but no. 31 revealed a trend to diminished phosphate excretion in
the fourth balance period.
Plasma levels of phosphate in patients 12 and 31 fell to
their lowest value by the eighth day after injection. Patient
no. 24 showed a rise in plasma phosphate two days after growth
hormone, and this rise tended to be sustained throu^iout the
remainder of the balance period. These findings are similar to
those of Bergenstal and Lipsett (1960)andBsck etal(l960), who found
phosphorus retention in five subjects and a tendency for the serum
inorganic phosphate to rise during short-term treatment with
growth hormone. Sustained elevation of serum inorganic phosphate
and alkaline phosphatase were only seen during long-term therapy.
In hypophysectomised rats and in "pituitary dwarfs" serum
phosphorus and alkaline phosphatase increased with prolonged use
of growth hormone (Saben, 1959)•
Patient no. 12 revealed a significant drop in alkaline
phosphatase after injection and this was sustained throughout the
remainder of the balance. No change was seen in no. }1.
Potassium Metabolism.
Patient no. 24 showed an increased faecal excretion of
potassium in the five days following the administration of growth
hormone,which was not seen in the other children. In no. 12 there
was a sharp reduction in urinary potassium in the first
twenty-four hours after injection, and patient no. 24 showed some
reduction in the first forty-eight hours. Both children showed a
maximal rise in the plasma level of potassium three to four days
after injection. The reduction in urinary potassium paralleled
that of urinary nitrogen in these children.
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Beck et si, (i960) described similar changes in three of
their patients in whom the pattern of nitrogen retention was
closely parallel to that of potassium retention. They also found
that decreased potassium excretion usually occurred during the
first twenty-four hours after the administration of growth hormone.
Patient no. 31 showed decreased levels of urinary potassium
in the seventh to the eleventh day after growth hormone but no
significant change was seen in no. 33. This patient had a
moderate degree of impairment of adrenocortical function. Both
children showed no significant change in plasma potassium.
Sodium Metabolism.
In patient no. 31 the faecal values for sodium were almost
doubled in the first ten days after hormone administration. No
change was apparent in the other children. No. 24 showed an
increased urinary excretion of sodium within the twenty-four hours
Immediately after injection, but this was not sustained.
Patient no, 31 had a significant reduction in urinary sodium on
the second day, thereafter there was a tendency to less positive
balance in the succeeding six days. This was followed by a large
esteret ion on the ninth day. Patients 12 and 33 showed no change
in urinary excretion of sodium. Both 12 and 24 experienced a
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sharp drop in plasma sodium within twenty-four hours of injaotion,
whereas 31 and 33 showed an increase seven days and four days after
hormone, respectively.
Beck and his colleagues (i960) described a positive sodium
balance in five patients during the administration of growth
hormone and in three of these patients the positive sodium balance
coincided with an increase in urinary aldosterone. The
significance and interpretation of this finding are not clear
because two of Beck's patients, who had a marked increase in
urinary aldosterone, showed little change in sodium balance. It
was suggested by Beck that this increase was in part dependent on
the dose of growth hormone given and he also mentioned the
possibility that the growth hormone preparation contained some
substance which was capable of stimulating aldosterone secretion.
Venning and Lucis (i960) studied the mechanism of action of
human, monkey and porcine growth hormone on aldosterone secretion
in human and rat adrenals, and they concluded that growth hormone
does not directly stimulate aldosterone secretion in vitro. These
workers also found that when growth hormone is administered to
intact and to hypophysectooised rets, the adrenals of these
animals secrete increased amounts of aldosterone. They also found
that the plasma of hypophysectomised rats treated with growth
hormone appeared to contain a substance which stimulated
aldosterone secretion in vitro.
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Plasma Alkaline Phosphatase.
Beck et al. (i960) described a rise in serum alkaline
phosphatase only on prolonged therapy with Human Growth Hormone,
except in the case of a thirteen-year old hypopituitary dwarf who had
an elevated serum alkaline phosphatase before treatment, in spite
of adequate amounts of Vitamin D. After two injections of growth
hormone the levels of alkaline phosphatase dropped, a similar fall
occurring in patient no. 12 after one injection. There was a
significant drop in alkaline phosphatase which was sustained
throughout the balance period, Ho change was detected in
patient no, 31•
Plasma Creatinine. Plasma Chloride and Plasma T,C0^«
No significant changes were seen in these determinations,
patient no, 31 showed a slight rise in creatinine in the first
twenty-four hours after injection but this was not continued.
Again, the T.COg and chloride in no. 31 showed a tendency to rise
from the fifth to the eleventh days after hormone. These findings
are similar to those of Beck et al. (i960) and Bergenstal and
Lipsett (i960).
The findings in these metabolic studies in children with
defective pituitary function confirm the potent but variable
2lC
metabollo action of Human Growth Hormone which have been described
by others (e.g. Beck et al,, I960; Ikkos and Luft, I960; Hanna,
Harrison, Maclntyre and Fraser, I960)* There was, however, no
evidence of increased urinary calcium output after the
administration of growth hormone and reasons for this observation
have been discussed*
SECTION 3
METHOna OF ASSAY OF HUMAN
GROWTH HORMONE
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METHODS OF ASSAY OF HUMAN GROWTH HORMONE
There is no chemical means of measuring Human Growth Hormone
and most attempts at estimation have employed a bioassay, the best
known being that described by Greenspan, Li, Simpson and Evans
(1949)• This method is based upon the increase in width which
occurs in the proximal tibial epiphyseal cartilage in the
hypophysectoaised rat, after the administration of Growth Hormone.
However, the assay is relatively insensitive and demands large
amounts of material.
Reports by Collip and Anderson (1934) and by Young (1938)
described the production of antisera to Thyrotropic Hormone and
Prolactin respectively, and such early demonstrations of the
antigenicity of pituitary hormones were rapidly exploited with the
isolation of purified pituitary extracts of high specific
activity.
In spite of a reported molecular weight of 27,100 (Li,1957),
Human Growth Hormone is a poor antigen, but its antigenicity may
be enhanced by the use of a mineral oil and lanolin adjuvant
(Ramon, Lemetayer and Richou, 1935) or by the use of Fround's
complete adjuvant, which is a suspension of mycobaoterium
butyricum in light mineral oil (Freund, 1951)• Such adjuvants
have wide applications and their use has facilitated the
production of potent antisera to Human Growth Hormone (Read and
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Stone, 1958? Hayashida and Li, 1958), and thereby led to the
development of methods of immunoassay (Read and Stone, 1958?
Read, i960).
The work to be described was undertaken in an attempt to
establish Read's assay which is based upon the haemagglutination
technique desoribed by Boyden (1951) and in which the major
assumption is made that Growth Hormone in serum is immunologically
related to Growth Hormone obtained from pituitary extracts. The
assay may be considered in three stages.
In the first stage, sheep red cells are treated with a
dilute solution of tannic acid and then they are incubated with a
solution of Human Growth Hormone which is assumed to become
adsorbed to the red cell surface. When a constant amount of
Growth Hormone coated cells is added to increasing dilutions of
antiserum, agglutination occurs where specific antibody is
present•
In the second stage of the assay, known concentrations of
Human Growth Hormone in decreasing amount are added to a suitable
dilution of specific rabbit antiserum, and the Growth Hormone
conjugated cells are agglutinated in those tubes which contain
insufficient Growth Hormone to inactivate the antibody present.
In the final stage, dilutions of human serum are used in
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place of Growth Hormone standards, and the dilution which first
inhibits haeraagglutination is determined. This dilution contains
the same amount of Growth Hormone which inhibits haemagglutination
in stage two, and thus the concentration of serum Growth Hormone
can be calculated.
Production of Antiserum to Human Growth Hormone.
Two male Dutch rabbits, aged three months and weighing 2.8
and 2.9 kilograms respectively, were bled from the right marginal
ear vein into sterile, chemically clean glass containers. The
first animal received 1 mg. H.G.H, (M.R.C. Raben preparation) in
complete Freund's adjuvant (Difco) subcutaneously and
intraperitoneally in a volume of 1 ml. at each site. The second
rabbit was given 1 mg. thrice-crystallised Ovalbumin (Light) in
the same manner and by the same routes. This constituted a
positive control for the assay using a "pure™ protein antigen.
Injections were given weekly for four weeks, and after a
further test-bleeding, 1 mg. H.G.H. was given in a total volume of
2 ml. H.G.H. diluent (Glaxo) by the left marginal ear-vein in the
first animal. The second rabbit was given 1 mg. Ovalbumin
intravenously in 2 ml. 0,9^ w/v sterile saline.
The presence of antibody to Human Growth Hormone was
confirmed by the classical ring precipitin technique and a
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precipitate was detected at an antiserum dilution of 1:256.
Antibody to ovalbumin was detected by the same method in an
antiserum dilution of 1:2048. The animals were bled by cardiac
puncture on the forty-third day after the first injection, the
blood was allowed to stand at 37°C for one hour, the clots were
"ringed", and the sera were left to separate overnight at 4°C.
They were then distributed in sterile "bijou" containers and
stored at -20°C until further use.
Confirmation of the Presence of Antibody to Human growth Hormone.
The presence of antibody to Human Growth Hormone was
confirmed by precipitin ring test, gel-diffusion in agar (Sell,
1955) and gel-diffusion in tubes (Oakley and Fulthorpe, 1953)•
The presence of univalent antibody in high titre was confirmed by
Dr. F.C.Greenwood by the method of diffusion in cellulose acetate
(Kohn, I960). On preliminary titration of the antiserum against
tannic-acid treated, Growth Hormone conjugated sheep cells, an
end-point was obtained between 1:25,600 and 1:51,200. Sera
obtained before injection of the antigen gave no precipitates in
the systems described, nor did they cause haemagglutination of
Growth Hormone conjugated sheep cells.
Gell diffusion studies with this and subsequent antisera
showed no precipitation with ovalbumin (Light) Human Serum Albumin
(Lister Institute, Batch no. EPA 133) and porcine adrenocortico-
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trophic hormone (Armour, Batch no. EE 1004)• The first antiserum
gave no precipitate with Human Gamma Globulin (Lister Institute,
Batch no. EG 105) but a later preparation formed a well-defined
band on diffusion against the same batch of gamma globulin. It
was not possible to cariy out diffusion studies against
preparations of other human pituitary hormones because they were
not available at that time. Attempts to demonstrate precipitation
by immuno-electrophoresis on cellulose acetate (Xohn, i960) were
unsuccessful.
Method of Assay.
The method followed was that of Read (i960) with certain
modifications.
Glassware.
All glass-ware was cleansed in hot "Fyroneg" solution,
washed overnight in cold running water, and finally rinsed ten
times in ion-free distilled water. All haemagglutination tubes
(soda-glass) were carefully inspected before use to ensure (as far
as possible) uniformity of the inner bottom surface.




The buffers were prepared in accordance with the directions
given by Read (i960), In initial experiments, solutions were
prepared from stock, but in later experiments all buffers were
freshly made up the day before an attempt at assay. All chemicals
used were A.R. quality.
guinea Pig Sera.
guinea pig blood was obtained by cardiac puncture from old
boar guinea pigs. It was allowed to clot, and after one hour at
37°C, the clots were "ringed" and the sera separated overnight
at 4°C.
C^ella .
All untreated red cells were washed and spun in an M.S.E.
"Major" centrifuge at 2,500 r.p.m. Tannic acid treated eells and
growth Hormone conjugated cells were centrifugea at 2,000 r.p.m.
The percentage composition of each red cell suspension was
determined on a micro-haematocrit (Hawksley).
Results.
Human group 0 Rhesus positive cells were used initially
217
because a ready source was available, but no consistent results
were obtained in the antiserum titration, Guinea pig cells and
formalinised sheep cells (Burroughs Wellcome) were also
unsuccessful. Finally, it was decided to use fresh sheep cells
(Burroughs Wellcome) and it was possible to titrate antiserum on
three successive weeks and obtain good reproduction (a one or two
tube difference) on titrations set up in triplicate.
Similar findings were obtained on titration with G-rowth
Hormone standards, but stage three of the assay, using unknown
sera, gave inconsistent results. At times an end-point could be
read but repetition within two days showed complete
haemagglutination in all the tests. On other occasions an
end-point would be determined but some or all of the controls
would show complete haemagglutination.
On enquiry, it was found that the sheep cells (Burroughs
Wellcome) were pooled on the day of collection, and the time from
collection to delivery was subject to one or two days variation.
Following the example of Ehrlich and Handle (1961), one sheep was
used for bleeding. A Southdown ram was kept for this purpose at
the country branch of the Hospital for Sick Children, and this was
bled as required by external jugular puncture. These cells gave
satisfactory results, reproducible to within one or two tubes
on three successive occasions at weekly intervals in stages one
and two of the assay, but again the assay of human serum was
unsatisfactory.
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Two technical problems were encountered in the method and
these could not be overcome* The first was concerned with the
preparation of the tannic acid treated, Growth Hormone conjugated
cells. It was not possible to use these cells within thirty
minutes of preparation in the third stage of the assay, and there
was a possibility that elution of the hormone might have occurred
within that time, although attempts to demonstrate hormone in the
supernatant by diffusion on cellulose acetate were unsuccessful.
The second problem was met in the preparation of a uniform
suspension of "tanned" or conjugated red cells. It was found that
satisfactory red cell suspensions could only be made by agitation
on a "Vortex" eccentric mixer and this invariably gave rise to red
cell breakdown which could be detected as a faint ragged line
around a non-haemagglutinated "button" of cells in control tubes,
when the mechanical mixer was used.
In view of the difficulties in standardising all the steps in
Head's method and because of the disadvantage in having an
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